NHS England Drugs List v15 2020 2021 PDF

MEDICINES NOT REIMBURSED THROUGH NATIONAL PRICES AND DIRECTLY COMMISSIONED BY NHS ENGLAND
VERSION 15 PUBLISHED APRIL 2020
SUITABLE FOR
SUITABLE FOR
SPECIALIST SHARED CARE
SHARED CARE
CENTRE ONLY BETWEEN
PRIOR WITH PRIMARY
(includng SPECIALIST
APPROVAL CARE (IF
DRUG NAME INDICATION COMMISSIONER PBR CATEGORY TA/POLICY STARTING CRITERIA STOPPING CRITERIA MONITORING/AUDIT REQUIREMENTS outreach when AND
PROFORMA SUPPORTED BY
delivered as part SECONDARY
REQUIRED LOCAL
of a provider CARE VIA
PRESCRIBING
network) NETWORK
COMMITTEE)
MODEL
HIV IN COMBINATION WITH OTHER ANTI-
ABACAVIR NHS ENGLAND AIDS/HIV ANTIRETROVIRALS AGREED REGIONALGUIDELINES BHIVA GUIDELINES (8) BHIVA GUIDELINES (8) HARS DATASET √
RETROVIRAL DRUGS
NHS ENGLAND CLINICAL

NHS ENGLAND AIDS/HIV ANTIRETROVIRALS COMMISSIONING POLICY: BHIVA GUIDELINES (8) BHIVA GUIDELINES (8) HARS DATASET √
ABACAVIR + LAMIVUDINE + RETROVIRAL DRUGS
B06/P/b/AGREED REGIONAL GUIDELINES
DOLUTEGRAVIR (TRIUMEQ®)
ABACAVIR + LAMIVUDINE NHS ENGLAND AIDS/HIV ANTIRETROVIRALS AGREED REGIONALGUIDELINES BHIVA GUIDELINES (8) BHIVA GUIDELINES (8) HARS DATASET √
RETROVIRAL DRUGS
ABALOPARATIDE DRUGS AFFECTING BONE
MALE AND JUVENILE OSTEOPOROSIS NHS ENGLAND NOT ROUTINELY COMMISSIONED AS PER IFR APPROVAL AS PER IFR APPROVAL AS PER IFR APPROVAL √
METABOLISM

ABATACEPT JUVENILE ARTHRITIS-PAEDIATRIC NHS ENGLAND CYTOKINE MODULATORS NHS ENGLAND POLICY NHS ENGLAND POLICY NHS ENGLAND POLICY √ √
COMMISSIONING POLICY: E03/P/d; TA 373
TA259, 387 (SEE ALSO SSC1438)

NICE/NHS ENGLAND POLICY NICE
ABIRATERONE CANCER NHS ENGLAND HORMONE ANTAGONISTS ONLY IN ENZALUTAMIDE NAÏVE SACT √ √
PATIENTS

ADALIMUMAB JUVENILE ARTHRITIS-PAEDIATRIC NHS ENGLAND CYTOKINE MODULATORS NHS ENGLAND POLICY NHS ENGLAND POLICY NHS ENGLAND POLICY √ √
ADALIMUMAB UVEITIS - ADULTS NHS ENGLAND CYTOKINE MODULATORS TA460 NICE NICE NICE AUDIT √ √
HIGHLY SPECIALISED HIGHLY SPECIALISED

ADALIMUMAB BEHCETS SYNDROME NHS ENGLAND CYTOKINE MODULATORS HIGHLY SPECIALISED CRITERIA ONLY HIGHLY SPECIALISED CRITERIA √
CRITERIA ONLY CRITERIA ONLY
ADALIMUMAB HIDRADENITIS SUPPURATIVA NHS ENGLAND CYTOKINE MODULATORS NICE TA 392 NICE NICE NICE AUDIT √ √
ADALIMUMAB PLAQUE PSORIASIS IN CHILDREN NHS ENGLAND CYTOKINE MODULATORS NICE TA 455 NICE NICE NICE AUDIT √ √
VIRAL HEPATITIS (B&C) & NOT ROUTINELY COMMISSIONED
ADEFOVIR HEPATITIS B NHS ENGLAND AS PER IFR APPROVAL AS PER IFR APPROVAL AS PER IFR APPROVAL √
RESPIRATORY SYNCYTIAL VIRUS (CG165)
AFATINIB CANCER NHS ENGLAND CANCER EXCLUSION TA310 NICE NICE SACT √
NOT ROUTINELY COMMISSIONED

AFLIBERCEPT CANCER NHS ENGLAND CANCER EXCLUSION AS PER IFR APPROVAL AS PER IFR APPROVAL SACT √
(TA307)
DRUGS USED IN METABOLIC HIGHLY SPECIALISED HIGHLY SPECIALISED

AGALSIDASE ALFA FABRY'S DISEASE NHS ENGLAND NHS ENGLAND SERVICE SPECIFICATION HIGHLY SPECIALISED DATABASE √
DISORDERS CRITERIA ONLY CRITERIA ONLY
AGALSIDASE BETA FABRY'S DISEASE NHS ENGLAND NHS ENGLAND SERVICE SPECIFICATION HIGHLY SPECIALISED DATABASE √
ALBUTROPIN ADULT ONSET GROWTH HORMONE
DEFICIENCY GROWTH HORMONE & GROWTH
NHS ENGLAND NOT ROUTINELY COMMISSIONED AS PER IFR APPROVAL AS PER IFR APPROVAL AS PER IFR APPROVAL √
HORMONE RECEPTOR ANTAGONIST
ALDESLEUKIN CANCER NHS ENGLAND IMMUNOMODULATING DRUGS NOT ROUTINELY COMMISSIONED AS PER IFR APPROVAL AS PER IFR APPROVAL SACT √
DRUGS AFFECTING THE IMMUNE TA312 AND NHS ENGLAND POLICY
ALEMTUZUMAB MULTIPLE SCLEROSIS NHS ENGLAND NICE NICE NICE AUDIT √ √****
RESPONSE STATEMENT 170075P
TRUST GUIDELINES: ISLET
PRE-TRANSPLANT DRUGS AFFECTING THE IMMUNE
ALEMTUZUMAB NHS ENGLAND TRANSPLANTATION (ONLY IF PROVIDED TRUST GUIDELINES TRUST GUIDELINES √
IMMUNOSUPPRESSION RESPONSE
AT ZERO DRUG COST)
DRUGS AFFECTING THE IMMUNE TRUST GUIDELINES: (ONLY IF PROVIDED
ALEMTUZUMAB CLL NHS ENGLAND TRUST GUIDELINES TRUST GUIDELINES SACT √
RESPONSE AT ZERO DRUG COST)
HIGHLY SPECIALISED CRITERIA ONLY
ALEMTUZUMAB BEHCETS SYNDROME NHS ENGLAND CYTOKINE MODULATORS (ONLY IF PROVIDED AT ZERO DRUG HIGHLY SPECIALISED CRITERIA √
COST)
ALGLUCOSIDASE ALFA POMPE DISEASE NHS ENGLAND NHS ENGLAND SERVICE SPECIFICATION HIGHLY SPECIALISED DATABASE √
DRUGS USED IN METABOLIC
ALIPOGENE TIPARVOVEC LIPOPROTEIN LIPASE DEFICIENCY NHS ENGLAND NOT ROUTINELY COMMISSIONED AS PER IFR APPROVAL AS PER IFR APPROVAL AS PER IFR APPROVAL √
DISORDERS
VIRAL HEPATITIS (B&C) &
ALISPORIVIR HEPATITIS C NHS ENGLAND NOT ROUTINELY COMMISSIONED AS PER IFR APPROVAL AS PER IFR APPROVAL AS PER IFR APPROVAL √
RESPIRATORY SYNCYTIAL VIRUS
ALPHA MANNOSIDASE DRUGS USED IN METABOLIC
ALPHA MANNOSIDASE DEFICIENCY NHS ENGLAND NOT ROUTINELY COMMISSIONED AS PER IFR APPROVAL AS PER IFR APPROVAL AS PER IFR APPROVAL √
RECOMBINANT HUMAN DISORDERS
VASODILATOR ANTIHYPERTENSIVE
AMBRISENTAN PULMONARY ARTERIAL HYPERTENSION NHS ENGLAND DRUGS/PULMANORY ARTERIAL NHS ENGLAND POLICY NHS ENGLAND POLICY AS PER POLICY √
COMMISSIONING POLICY: A11/P/c
HYPERTENSION
AMIFAMPRIDINE PHOSPHATE LEMS NHS ENGLAND NEUROMUSCULAR DISORDERS AS PER IFR APPROVAL AS PER IFR APPROVAL AS PER IFR APPROVAL √
NHS ENGLAND POLICY: 16009/P
AMIKACIN INHALATION CYSTIC FIBROSIS NHS ENGLAND ANTIBACTERIAL DRUGS NOT ROUTINELY COMMISSIONED AS PER IFR APPROVAL AS PER IFR APPROVAL AS PER IFR APPROVAL √
CYSTIC FIBROSIS
AMIKACIN LIPOSOMAL NHS ENGLAND ANTIBACTERIAL DRUGS NOT ROUTINELY COMMISSIONED AS PER IFR APPROVAL AS PER IFR APPROVAL AS PER IFR APPROVAL √
NUMBER OF PATIENTS TREATED

AMPHOTERICIN LIPOSOMAL FUNGAL INFECTION NHS ENGLAND ANTIFUNGALS AGREED TRUST GUIDELINES TRUST GUIDELINES TRUST GUIDELINES PROPORTION GIVEN FOR SPC √
INDICATIONS WITHIN POLICY
DRUGS AFFECTING THE IMMUNE
ANABASUM SCLERODERMA NHS ENGLAND NOT ROUTINELY COMMISSIONED AS PER IFR APPROVAL AS PER IFR APPROVAL AS PER IFR APPROVAL √
RESPONSE
ANAKINRA JUVENILE ARTHRITIS-PAEDIATRIC NHS ENGLAND CYTOKINE MODULATORS NHS ENGLAND POLICY NHS ENGLAND POLICY NHS ENGLAND POLICY √ √
COMMISSIONING POLICY: E03/P/d
PERIODIC FEVERS AND NHS ENGLAND CLINICAL
ANAKINRA NHS ENGLAND CYTOKINE MODULATORS NHS ENGLAND POLICY NHS ENGLAND POLICY NHS ENGLAND POLICY √ √
AUTOINFLAMMATORY CONDITIONS COMMISSIONING POLICY: 170062P
CRYOPYRIN ASSOCIATED PERIODIC CRYOPYRIN ASSOCIATED PERIODIC HIGHLY SPECIALISED HIGHLY SPECIALISED
ANAKINRA NHS ENGLAND CYTOKINE MODULATORS HIGHLY SPECIALISED DATABASE √
SYNDROME SYNDROME SERVICE SPECIFICATION CRITERIA ONLY CRITERIA ONLY
ANAKINRA ADULT ONSET STILLS DISEASE NHS ENGLAND CYTOKINE MODULATORS NHS ENGLAND POLICY NHS ENGLAND POLICY NHS ENGLAND POLICY √ √
COMMISSIONING POLICY: 170056P
ANIDULAFUNGIN FUNGAL INFECTION NHS ENGLAND ANTIFUNGALS AGREED TRUST GUIDELINES TRUST GUIDELINES TRUST GUIDELINES PROPORTION GIVEN FOR SPC √
ANIFROLUMAB SLE NHS ENGLAND CYTOKINE MODULATORS NOT ROUTINELY COMMISSIONED AS PER IFR APPROVAL AS PER IFR APPROVAL AS PER IFR APPROVAL √
APLASTIC ANAEMIA DRUGS USED IN HYPOPLASTIC,

ANTILYMPHOCYTE GLOBULIN NHS ENGLAND BCSH GUIDELINES BCSH GUIDELINES BCSH GUIDELINES √
ORGAN TRANSPLANT HAEMOLYTIC, AND RENAL ANAEMIAS
ANTIPSEUDOMONAS AERUGINOSA
CYSTIC FIBROSIS NHS ENGLAND ANTIBACTERIAL DRUGS NOT ROUTINELY COMMISSIONED AS PER IFR APPROVAL AS PER IFR APPROVAL AS PER IFR APPROVAL √
IgY
AS PER BCSH GUIDELINES FOR
ANTITHROMBIN III NHS ENGLAND BLOOD-RELATED PRODUCTS BCSH GUIDELINES BCSH GUIDELINES BCSH GUIDELINES √
SPECIALISED INDICATIONS
ANTITHYMOCYTE APLASTIC ANAEMIA DRUGS USED IN HYPOPLASTIC,

NHS ENGLAND BCSH GUIDELINES BCSH GUIDELINES BCSH GUIDELINES √
IMMUNOGLOBULIN ORGAN TRANSPLANT HAEMOLYTIC, AND RENAL ANAEMIAS
ARIMOCLOMOL NIEMANN-PICK DISEASE NHS ENGLAND NEUROMUSCULAR DISORDERS NOT ROUTINELY COMMISSIONED AS PER IFR APPROVAL AS PER IFR APPROVAL AS PER IFR APPROVAL √
NHS England drugs-list v15 2020-2021.xlsx NHSE Commissioned PbRE Drugv15 1 31/03/2020
SUITABLE FOR
SUITABLE FOR
SHARED CARE
CENTRE ONLY BETWEEN
PRIOR WITH PRIMARY
APPROVAL CARE (IF
REQUIRED LOCAL
PRESCRIBING
network) NETWORK
COMMITTEE)
MODEL
ASFOTASE ALFA HYPOPHOSPHATASIA NHS ENGLAND HST6 NICE NICE AS PER MAA √ √
DISORDERS
ASUNAPREVIR HEPATITIS C NHS ENGLAND NOT ROUTINELY COMMISSIONED AS PER IFR APPROVAL AS PER IFR APPROVAL AS PER IFR APPROVAL √
ATACICEPT SLE NHS ENGLAND NOT ROUTINELY COMMISSIONED AS PER IFR APPROVAL AS PER IFR APPROVAL AS PER IFR APPROVAL √
RESPONSE
ATALUREN DUCHENNE MUSCULAR DYSTROPHY NHS ENGLAND NEUROMUSCULAR DISORDERS NICE HST3 NICE NICE NORTHSTAR DATABASE √ √

ATAZANAVIR NHS ENGLAND AIDS/HIV ANTIRETROVIRALS AGREED REGIONALGUIDELINES BHIVA GUIDELINES (8) BHIVA GUIDELINES (8) HARS DATASET √
RETROVIRAL DRUGS
ATAZANAVIR + COBICISTAT HIV IN COMBINATION WITH OTHER ANTI-
NHS ENGLAND AIDS/HIV ANTIRETROVIRALS AGREED REGIONALGUIDELINES BHIVA GUIDELINES (8) BHIVA GUIDELINES (8) HARS DATASET √
(EVOTAZ®) RETROVIRAL DRUGS
AS PER NHS ENGLAND
AUTOLOGOUS SERUM EYE DROPS DRY EYE NHS ENGLAND BLOOD-RELATED PRODUCTS NHS ENGLAND POLICY NHS ENGLAND POLICY NHS ENGLAND POLICY √ √
LETTER/CIRCULAR
AVACOPAN ANCA-POSITIVE VASCULITIS NHS ENGLAND CYTOKINE MODULATORS NOT ROUTINELY COMMISSIONED AS PER IFR APPROVAL AS PER IFR APPROVAL AS PER IFR APPROVAL √
AXITINIB CANCER NHS ENGLAND PROTEIN KINASE INHIBITORS TA333 (also refer to circular SSC1508) NICE NICE SACT √
AZACITIDINE CANCER NHS ENGLAND MYELODYSPLASTIC SYNDROME TA218 NICE NICE SACT √
NHS ENGLAND CLINCAL
AZTREONAM LYSINE CYSTIC FIBROSIS NHS ENGLAND ANTIBACTERIAL DRUGS NHS ENGLAND POLICY NHS ENGLAND POLICY NHS ENGLAND POLICY √* √*
COMMISSIONING POLICY: A01/P/b
CYSTIC FIBROSIS (CONTINUOUS
AZTREONAM LYSINE NHS ENGLAND ANTIBACTERIAL DRUGS NHS ENGLAND CLINCAL AS PER IFR APPROVAL AS PER IFR APPROVAL AS PER IFR APPROVAL √
TREATMENT)
COMMISSIONING POLICY: 16001/P
BARDOXOLONE METHYL PULMONARY ARTERIAL HYPERTENSION NHS ENGLAND DRUGS/PULMANORY ARTERIAL NOT ROUTINELY COMMISSIONED AS PER IFR APPROVAL AS PER IFR APPROVAL AS PER IFR APPROVAL √
HYPERTENSION
CORTICOSTEROIDS AND OTHER
BASILIXIMAB RENAL TRANSPLANT NHS ENGLAND TA85 & TA99 NICE NICE √
IMMUNOSUPPRESSANTS
BECLABUVIR HEPATITIS C VIRAL HEPATITIS (B&C) &
BEDAQUILINE EXTENSIVELY DRUG RESITANT TB NHS ENGLAND ANTITUBERCULOSIS DRUGS NHS ENGLAND POLICY NHS ENGLAND POLICY NHS ENGLAND POLICY √ √
COMMISSIONING POLICY: F04/P/a
BEDAQUILINE MULTI DRUG RESITANT TB NHS ENGLAND ANTITUBERCULOSIS DRUGS NHS ENGLAND POLICY NHS ENGLAND POLICY NHS ENGLAND POLICY √ √
MALIGNANT DISEASE AND
BEGELOMAB GRAFT VERSUS HOST DISEASE NHS ENGLAND NOT ROUTINELY COMMISSIONED AS PER IFR APPROVAL AS PER IFR APPROVAL AS PER IFR APPROVAL √
IMMUNOSUPPRESSION
DRUGS AFFECTING THE IMMUNE NOT ROUTINELY COMMISSIONED - NICE
BELATACEPT RENAL TRANSPLANT NHS ENGLAND NICE TA IN PROGRESS NICE TA IN PROGRESS NICE TA IN PROGRESS √
RESPONSE TA IN PROGRESS
BELIMUMAB SLE NHS ENGLAND NICE TA 397 NICE NICE NICE AUDIT √ √
RESPONSE
BENRALIZUMAB ASTHMA NHS ENGLAND ALLERGEN IMMUNOTHERAPY NICE TA 565 NICE NICE NICE AUDIT √ √
BEPERMINOGENE PERPLASMID PERIPHERAL VASCULAR DISEASE NHS ENGLAND GENE THERAPY NOT ROUTINELY COMMISSIONED AS PER IFR APPROVAL AS PER IFR APPROVAL AS PER IFR APPROVAL √
BETAINE HOMOCYSTINURIA NHS ENGLAND NHS ENGLAND SERVICE SPECIFICATION HIGHLY SPECIALISED DATABASE √
BEVACIZUMAB CANCER CDF ANTINEOPLASTIC DRUGS CDF POLICY CDF CDF SACT √
AS PER NATIONAL PROTOCOL (SEE NF2 AS PER NATIONAL AS PER NATIONAL
BEVACIZUMAB NEUROFIBROMATOSIS NHS ENGLAND ANTINEOPLASTIC DRUGS AS PER NATIONAL PROTOCOL √
SERVICE SPEC) PROTOCOL PROTOCOL
BICTECRAVIR (IN COMINATION
HIV IN COMBINATION WITH OTHER ANTI- NHS ENGLAND CLINCAL
WITH EMTRICITABINE AND NHS ENGLAND AIDS/HIV ANTIRETROVIRALS NHS ENGLAND POLICY NHS ENGLAND POLICY HARS DATASET √
RETROVIRAL DRUGS COMMISSIONING POLICY: 170131P
TENOFOVIR ALAFENAMIDE)
BIMAGRUMAB INCLUSION BODY MYOSITIS NHS ENGLAND CYTOKINE MODULATORS NOT ROUTINELY COMMISSIONED AS PER IFR APPROVAL AS PER IFR APPROVAL AS PER IFR APPROVAL √
BIOTIN MULTIPLE SCLEROSIS NHS ENGLAND VITAMINS NOT ROUTINELY COMMISSIONED AS PER IFR APPROVAL AS PER IFR APPROVAL AS PER IFR APPROVAL √
SYSTEMIC LUPUS ERYTHEMATOSUS
BLISIBIMOD NHS ENGLAND CYTOKINE MODULATORS NOT ROUTINELY COMMISSIONED AS PER IFR APPROVAL AS PER IFR APPROVAL AS PER IFR APPROVAL √
(SLE)
ORGAN REJECTION POST KIDNEY
BORTEZOMIB NHS ENGLAND ANTINEOPLASTIC DRUGS (NHS ENGLAND CLINICAL AS PER IFR APPROVAL AS PER IFR APPROVAL AS PER IFR APPROVAL √
TRANSPLANT
COMMISSIONING POLICY: A07/P/c)
TA129, TA228, TA311, TA378, TA573

CDF POLICY
NHS ENGLAND/ NOT ROUTINELY COMMISSIONED NICE NICE
BORTEZOMIB CANCER ANTINEOPLASTIC DRUGS SACT √ √
CDF (NHS ENGLAND CLINICAL CDF CDF
COMMISSIONING POLICY: 170035P,
170074P)
BOSENTAN DIGITAL ULCERS NHS ENGLAND DRUGS/PULMANORY ARTERIAL NHS ENGLAND POLICY NHS ENGLAND POLICY NHS ENGLAND POLICY √ √
HYPERTENSION
BOSENTAN PULMONARY ARTERIAL HYPERTENSION NHS ENGLAND DRUGS/PULMANORY ARTERIAL NHS ENGLAND POLICY NHS ENGLAND POLICY AS PER POLICY √
HYPERTENSION
BOSUTINIB CANCER NHS ENGLAND CANCER EXCLUSION TA 401 NICE NICE SACT √ √
TORSION DYSTONIAS AND OTHER

BOTULINUM TOXIN FOCAL SPASTICITY IN CHILDREN NHS ENGLAND AGREED TRUST GUIDELINES TRUST GUIDELINES TRUST GUIDELINES AS PER POLICY √
INVOLUNTARY MOVEMENTS
INTRAVESICAL USE IN SPINAL CORD TORSION DYSTONIAS AND OTHER
BOTULINUM TOXIN*** NHS ENGLAND AGREED TRUST GUIDELINES TRUST GUIDELINES TRUST GUIDELINES AS PER POLICY √
INJURY INVOLUNTARY MOVEMENTS
ACUTE SENSORINEURAL HEARING
BRIMAPITIDE NHS ENGLAND PROTEIN KINASE INHIBITORS NOT ROUTINELY COMMISSIONED AS PER IFR APPROVAL AS PER IFR APPROVAL AS PER IFR APPROVAL √
LOSS
BRINCIDOFOVIR CYTOMEGALOVIRUS NHS ENGLAND CYTOMEGALOVIRUS INFECTION NOT ROUTINELY COMMISSIONED AS PER IFR APPROVAL AS PER IFR APPROVAL AS PER IFR APPROVAL √
BUROSUMAB X LINKED HYPOPHOSPHATAEMIA NHS ENGLAND HST 8 NICE NICE NICE AUDIT √ √
RESPONSE
HEREDITARY ANGIOEDEMA - ACUTE NHS ENGLAND CLINICAL
C1 ESTERASE INHIBITORS NHS ENGLAND ALLERGIC EMERGENCIES NHS ENGLAND POLICY NHS ENGLAND POLICY AS PER POLICY √
TREATMENT COMMISSIONING POLICY: B09/P/b
HEREDITARY ANGIOEDEMA - NHS ENGLAND CLINICAL
C1 ESTERASE INHIBITORS NHS ENGLAND ALLERGIC EMERGENCIES NHS ENGLAND POLICY NHS ENGLAND POLICY AS PER POLICY √ √
PROPHYLACTIC TREATMENT COMMISSIONING POLICY: 16045/P
HEREDITARY ANGIOEDEMA -
AS PER NHS ENGLAND CLINICAL
C1 ESTERASE INHIBITORS PROPHYLACTIC TREATMENT IN NHS ENGLAND ALLERGIC EMERGENCIES NHS ENGLAND POLICY NHS ENGLAND POLICY AS PER POLICY √ √
CHILDREN (CINRYZE ONLY)
CABOTEGRAVIR NHS ENGLAND AIDS/HIV ANTIRETROVIRALS NOT ROUTINELY COMMISSIONED AS PER IFR APPROVAL AS PER IFR APPROVAL AS PER IFR APPROVAL √
RETROVIRAL DRUGS
INBORN ERRORS IN PRIMARY BILE ACID
CALCIFIDIOL NHS ENGLAND OTHER ENDOCRINE DRUGS NOT ROUTINELY COMMISSIONED AS PER IFR APPROVAL AS PER IFR APPROVAL AS PER IFR APPROVAL √
SYNTHESIS
CRYOPYRIN ASSOCIATED PERIODIC NHS ENGLAND CLINICAL
CANAKINUMAB NHS ENGLAND IMMUNOMODULATING DRUGS NHS ENGLAND POLICY NHS ENGLAND POLICY AS PER POLICY √
FEVER SYNDROME COMMISSIONING POLICY: 200209P
CANAKINUMAB JUVENILE ARTHRITIS-PAEDIATRIC NHS ENGLAND IMMUNOMODULATING DRUGS AS PER IFR APPROVAL AS PER IFR APPROVAL AS PER IFR APPROVAL √
(TA302)
CANNABIDIOL (AS EPIDIOLEX) DRAVET/LENNOX GESTAUT SYNDROME NHS ENGLAND CANNABINOIDS TA615 & TA614 NICE NICE NICE AUDIT √ √
THROMBOTIC THROMBOCYTOPENIC NOT ROUTINELY COMMISSIONED

CAPLACIZUMAB NHS ENGLAND PLATELET DISORDER DRUGS AS PER IFR APPROVAL AS PER IFR APPROVAL AS PER IFR APPROVAL √
PUPURA (TA302)
SUITABLE FOR
SUITABLE FOR
SHARED CARE
CENTRE ONLY BETWEEN
PRIOR WITH PRIMARY
APPROVAL CARE (IF
REQUIRED LOCAL
PRESCRIBING
network) NETWORK
COMMITTEE)
MODEL
CARGLUMIC ACID UREA CYCLE DISORDERS NHS ENGLAND NHS ENGLAND SERVICE SPECIFICATION HIGHLY SPECIALISED DATABASE √
CARNITINE CARNITINE DEFICIENCY NHS ENGLAND NHS ENGLAND SERVICE SPECIFICATION HIGHLY SPECIALISED DATABASE √

CASPOFUNGIN FUNGAL INFECTION NHS ENGLAND ANTIFUNGALS AGREED TRUST GUIDELINES TRUST GUIDELINES TRUST GUIDELINES PROPORTION GIVEN FOR SPC √

CENEGERMIN NEUROTROPHIC KERATITIS NHS ENGLAND ATMP AS PER IFR APPROVAL AS PER IFR APPROVAL AS PER IFR APPROVAL √
(TA 532)
CERALIFIMOD MULTIPLE SCLEROSIS NHS ENGLAND IMMUNOMODULATING DRUGS NOT ROUTINELY COMMISSIONED AS PER IFR APPROVAL AS PER IFR APPROVAL AS PER IFR APPROVAL √
LYSOSOMAL STORAGE DISORDER
CERLIPONASE ALFA NEURONAL CEROID LIPOFUSCINOSIS NHS ENGLAND HST12 NICE NICE NICE AUDIT √ √
DRUGS
CETUXIMAB CANCER NHS ENGLAND ANTINEOPLASTIC DRUGS TA145, TA176 (replaced by TA439), TA473 NICE NICE SACT √ (not TA145) √
CEREBROTENDINOUS DRUGS USED IN METABOLIC NHS ENGLAND CLINICAL

CHENODEOXYCHOLIC ACID NHS ENGLAND NHS ENGLAND POLICY NHS ENGLAND POLICY √ √
XANTHOMATOSIS (CTX) DISORDERS COMMISSIONING POLICY 170127P
DRUGS USED IN METABOLIC NHS ENGLAND CLINICAL
CHENODEOXYCHOLIC ACID PRIMARY BILIARY CIRRHOSIS NHS ENGLAND NHS ENGLAND POLICY NHS ENGLAND POLICY √ √
DISORDERS COMMISSIONING POLICY 170127P
INBORN ERRORS IN PRIMARY BILE ACID DRUGS USED IN METABOLIC NHS ENGLAND CLINICAL
CHOLIC ACID NHS ENGLAND NHS ENGLAND POLICY NHS ENGLAND POLICY √ √
SYNTHESIS DISORDERS COMMISSIONING POLICY 170127P
CIDOFOVIR CYTOMEGALOVIRUS NHS ENGLAND CYTOMEGALOVIRUS INFECTION AGREED TRUST GUIDELINES TRUST GUIDELINES TRUST GUIDELINES PROPORTION GIVEN FOR SPC √
PRIMARY AND SECONDARY DRUGS FOR MINERAL BONE TA117 NICE NICE
CINACALCET NHS ENGLAND √
HYPERPARATHYROIDISM DISORDERS NHS ENGLAND POLICY 16034/P NHS ENGLAND POLICY NHS ENGLAND POLICY
CIPROFLOXACIN INHALATION CYSTIC FIBROSIS NHS ENGLAND ANTIBACTERIAL DRUGS NOT ROUTINELY COMMISSIONED AS PER IFR APPROVAL AS PER IFR APPROVAL AS PER IFR APPROVAL √
CIPROFLOXACIN LIPOSOMAL CYSTIC FIBROSIS
NHS ENGLAND ANTIBACTERIAL DRUGS NOT ROUTINELY COMMISSIONED AS PER IFR APPROVAL AS PER IFR APPROVAL AS PER IFR APPROVAL √
(INHALED)
CLADRIBINE MULTIPLE SCLEROSIS NHS ENGLAND IMMUNOMODULATING DRUGS TA492, TA616 (Replaces TA492) NICE NICE NICE AUDIT √ √****
PULMONARY LANGERHANS
CLADRIBINE NHS ENGLAND IMMUNOMODULATING DRUGS NOT ROUTINELY COMMISSIONED AS PER IFR APPROVAL AS PER IFR APPROVAL AS PER IFR APPROVAL √
HISTIOCYTOSIS
CLAZAKIZUMAB ANTIBODY MEDICATED REJECTION NHS ENGLAND CYTOKINE MODULATORS NOT ROUTINELY COMMISSIONED AS PER IFR APPROVAL AS PER IFR APPROVAL AS PER IFR APPROVAL √

COBICISTAT NHS ENGLAND AIDS/HIV ANTIRETROVIRALS COMMISSIONING POLICY: NHS ENGLAND POLICY NHS ENGLAND POLICY HARS DATASET √
RETROVIRAL DRUGS
F03/P/b/AGREED REGIONAL GUIDELINES

CO-CARELDOPA INTESTINAL GEL PARKINSON'S DISEASE NHS ENGLAND NEURODEGENERATIVE CONDITIONS NHS ENGLAND POLICY NHS ENGLAND POLICY NHS ENGLAND POLICY √ √
COMMISSIONING POLICY: D04/P/e
NHS ENGLAND POLICY NHS ENGLAND POLICY NHS ENGLAND POLICY
COLISTIMETHATE SODIUM CYSTIC FIBROSIS NHS ENGLAND ANTIBACTERIAL DRUGS COMMISSIONING POLICY: A01/P/b √* √*
NICE NICE NICE AUDIT
TA276
CONESTAT ALFA NHS ENGLAND ALLERGIC EMERGENCIES NHS ENGLAND POLICY NHS ENGLAND POLICY AS PER POLICY √
TREATMENT ONLY COMMISSIONING POLICY: B09/P/b
CRIZANLIZUMAB SICKLE CELL DISEASE NHS ENGLAND IMMUNOMODULATING DRUGS NOT ROUTINELY COMMISSIONED AS PER IFR APPROVAL AS PER IFR APPROVAL AS PER IFR APPROVAL √
NICE TA 406, 422 NICE NICE
CRIZOTINIB CANCER NHS ENGLAND/CDF PROTEIN KINASE INHIBITORS SACT √ √
CDF (TA 529) CDF CDF
CYCLIC PYRANOPTERIN DRUGS USED IN METABOLIC
MOLYBDENUM COFACTOR DEFICIENCY NHS ENGLAND NOT ROUTINELY COMMISSIONED AS PER IFR APPROVAL AS PER IFR APPROVAL AS PER IFR APPROVAL √
MONOPHOSPHATE DISORDERS
CYSTEAMINE (MERCAPTAMINE) NEPHROPATHIC CYSTINOSIS NHS ENGLAND NHS ENGLAND SERVICE SPECIFICATION HIGHLY SPECIALISED DATABASE √
DABRAFENIB CANCER NHS ENGLAND PROTEIN KINASE INHIBITORS TA321, TA396 & TA 544 NICE NICE SACT √ (not TA321) √
DACLIZUMAB MULTIPLE SCLEROSIS NHS ENGLAND IMMUNOMODULATING DRUGS NOT ROUTINELY COMMISSIONED AS PER IFR APPROVAL AS PER IFR APPROVAL AS PER IFR APPROVAL √
DRUGS USED IN HYPOPLASTIC, RENAL DIALYSIS ONLY, INCLUDING VIA
PRODUCT WITH LOWEST
DARBOPOETIN ALPHA DIALYSIS-INDUCED ANAEMIA NHS ENGLAND HAEMOLYTIC, AND RENAL ANAEMIAS - OUTPATIENTS, AND ONLY AS PER NICE TRUST GUIDELINES TRUST GUIDELINES √
PROCUREMENT COST TO BE USED
IRON OVERLOAD CG114
DARUNAVIR NHS ENGLAND AIDS/HIV ANTIRETROVIRALS AGREED REGIONALGUIDELINES BHIVA GUIDELINES (8) BHIVA GUIDELINES (8) HARS DATASET √
RETROVIRAL DRUGS
DARUNAVIR + COBICISTAT NHS ENGLAND AIDS/HIV ANTIRETROVIRALS AGREED REGIONALGUIDELINES BHIVA GUIDELINES (8) BHIVA GUIDELINES (8) HARS DATASET √
RETROVIRAL DRUGS
DASABUVIR HEPATITIS C NHS ENGLAND TA 365 AS PER RUN RATE CARD AS PER RUN RATE CARD HEPATITIS C MDS √ √
DASATINIB CANCER NHS ENGLAND PROTEIN KINASE INHIBITORS NICE TA 425, 426 NICE NICE SACT √ √

DECITABINE CANCER NHS ENGLAND MYELODYSPLASTIC SYNDROME AS PER IFR APPROVAL AS PER IFR APPROVAL SACT √
(TA270)
DRUGS USED IN HYPOPLASTIC,
IRON CHELATION IN THALASSAEMIA NHS ENGLAND CLINICAL QUALITY DASHBOARD/ NATIONAL
DEFERASIROX NHS ENGLAND HAEMOLYTIC, AND RENAL ANAEMIAS - NHS ENGLAND POLICY NHS ENGLAND POLICY √
AND SICKLE CELL COMMISSIONING POLICY 16070/P HAEMOGLOBINOPATHY REGISTRY
IRON OVERLOAD
DEFERIPRONE** NHS ENGLAND HAEMOLYTIC, AND RENAL ANAEMIAS - NHS ENGLAND POLICY NHS ENGLAND POLICY √
IRON OVERLOAD
DEFIBROTIDE HEPATIC VENO-OCCLUSIVE DISEASE NHS ENGLAND BLOOD-RELATED PRODUCTS NHS ENGLAND POLICY NHS ENGLAND POLICY NHS ENGLAND POLICY √ √
COMMISSIONING POLICY: B04/P/c
DELAMANID EXTENSIVELY DRUG RESITANT TB NHS ENGLAND ANTITUBERCULOSIS DRUGS NHS ENGLAND POLICY NHS ENGLAND POLICY NHS ENGLAND POLICY √ √
DELAMANID MULTI DRUG RESITANT TB NHS ENGLAND ANTITUBERCULOSIS DRUGS NHS ENGLAND POLICY NHS ENGLAND POLICY NHS ENGLAND POLICY √ √
DESFERRIOXAMINE** NHS ENGLAND HAEMOLYTIC, AND RENAL ANAEMIAS - NHS ENGLAND POLICY NHS ENGLAND POLICY √
IRON OVERLOAD
DEXRAZOXANE ANTHRACYCLINE EXTRAVASATION NHS ENGLAND IMMUNOMODULATING DRUGS AGREED TRUST GUIDELINES TRUST GUIDELINES TRUST GUIDELINES √

DEXRAZOXANE ANTHRACYCLINE CARDIOTOXICITY NHS ENGLAND IMMUNOMODULATING DRUGS NHS ENGLAND POLICY NHS ENGLAND POLICY AS PER IFR APPROVAL √ √
COMMISSIONING POLICY 200204P

DIBOTERMIN ALFA COMPLEX SPINAL SURGERY NHS ENGLAND BONE MORPHOGENETIC PROTEIN NHS ENGLAND POLICY NHS ENGLAND POLICY AUDIT, BSR REGISTRY √
COMMISSIONING POLICY 16063/P
PRIMARY HYPO AND HYPERKALAEMIC

DICHLORPHENAMIDE NHS ENGLAND NEUROMUSCULAR DISORDERS NOT ROUTINELY COMMISSIONED AS PER IFR APPROVAL AS PER IFR APPROVAL AS PER IFR APPROVAL √
PERIODIC PARALYSIS

DIDANOSINE NHS ENGLAND AIDS/HIV ANTIRETROVIRALS AGREED REGIONALGUIDELINES BHIVA GUIDELINES (8) BHIVA GUIDELINES (8) HARS DATASET √
RETROVIRAL DRUGS
DIMETHYL FUMARATE MULTIPLE SCLEROSIS NHS ENGLAND IMMUNOMODULATING DRUGS TA320 NICE NICE NICE AUDIT √ √****
DIROXIMEL FUMARATE MULTIPLE SCLEROSIS NHS ENGLAND IMMUNOMODULATING DRUGS NOT ROUTINELY COMMISSIONED AS PER IFR APPROVAL AS PER IFR APPROVAL AS PER IFR APPROVAL √
DOLUTEGRAVIR NHS ENGLAND AIDS/HIV ANTIRETROVIRALS COMMISSIONING POLICY: B06/P/a/ NHS ENGLAND POLICY NHS ENGLAND POLICY HARS DATASET √
RETROVIRAL DRUGS
AGREED REGIONAL GUIDELINES
DOMAGROZUMAB DUCHENNE MUSCULAR DYSTROPHY NHS ENGLAND NEUROMUSCULAR DISORDERS NOT ROUTINELY COMMISSIONED AS PER IFR APPROVAL AS PER IFR APPROVAL AS PER IFR APPROVAL √
SUITABLE FOR
SUITABLE FOR
SHARED CARE
CENTRE ONLY BETWEEN
PRIOR WITH PRIMARY
APPROVAL CARE (IF
REQUIRED LOCAL
PRESCRIBING
network) NETWORK
COMMITTEE)
MODEL
HIV iN COMBINATION WITH OTHER ANTI- NHS ENGLAND CLINCAL
DORAVIRINE NHS ENGLAND AIDS/HIV ANTIRETROVIRALS NHS ENGLAND POLICY NHS ENGLAND POLICY HARS DATASET √
RETROVIRAL DRUGS COMMISSIONING POLICY: 190137P
DORNASE ALFA PRIMARY CILIARY DYSKINESIA NHS ENGLAND MUCOLYTICS AS PER IFR APPROVAL AS PER IFR APPROVAL AS PER IFR APPROVAL √
NHS ENGLAND POLICY 16029/P
DORNASE ALFA CYSTIC FIBROSIS NHS ENGLAND MUCOLYTICS NHS ENGLAND POLICY NHS ENGLAND POLICY NHS ENGLAND POLICY √* √*
DRISAPERSEN DUCHENNE MUSCULAR DYSTROPHY NHS ENGLAND NEUROMUSCULAR DISORDERS NOT ROUTINELY COMMISSIONED AS PER IFR APPROVAL AS PER IFR APPROVAL AS PER IFR APPROVAL √

DUPILUMAB ASTHMA NHS ENGLAND NOT ROUTINELY COMMISSIONED AS PER IFR APPROVAL AS PER IFR APPROVAL AS PER IFR APPROVAL √
RESPONSE
HEREDITARY ANGIOEDEMA - ACUTE
ECALLANTIDE NHS ENGLAND ALLERGIC EMERGENCIES NOT ROUTINELY COMMISSIONED AS PER IFR APPROVAL AS PER IFR APPROVAL AS PER IFR APPROVAL √
TREATMENT ONLY
ORGAN REJECTION POST KIDNEY PAROXYSMAL NOCTURNAL NOT ROUTINELY COMMISSIONED
ECULIZUMAB NHS ENGLAND AS PER IFR APPROVAL AS PER IFR APPROVAL AS PER IFR APPROVAL √
TRANSPLANT HAEMOGLOBINURIA NHS ENGLAND POLICY: A07/P/b
C3 GLOMERULOPATHY (POST PAROXYSMAL NOCTURNAL NHS ENGLAND CLINICAL
ECULIZUMAB NHS ENGLAND NHS ENGLAND POLICY NHS ENGLAND POLICY NHS ENGLAND POLICY √ √
TRANSPLANT) HAEMOGLOBINURIA COMMISSIONING POLICY: 16054/P

PAROXYSMAL NOCTURNAL NHS ENGLAND POLICY NHS ENGLAND POLICY NHS ENGLAND POLICY
ECULIZUMAB AHUS NHS ENGLAND COMMISSIONING POLICY: E03/PS(HSS)/A √ √
HAEMOGLOBINURIA NICE NICE NICE
NICE HST1
NHS NATIONAL SPECIALISED

PAROXYSMAL NOCTURNAL PAROXYSMAL NOCTURNAL
ECULIZUMAB NHS ENGLAND COMMISSIONING TEAM SERVICE NSCT SERVICE SPEC NSCT SERVICE SPEC NSCT SERVICE SPEC √
HAEMOGLOBINURIA HAEMOGLOBINURIA
SPECIFICATION
EDASALONEXENT DUCHENNE MUSCULAR DYSTROPHY NHS ENGLAND NEUROMUSCULAR DISORDERS NOT ROUTINELY COMMISSIONED AS PER IFR APPROVAL AS PER IFR APPROVAL AS PER IFR APPROVAL √

EDRATIDE SLE NHS ENGLAND NOT ROUTINELY COMMISSIONED AS PER IFR APPROVAL AS PER IFR APPROVAL AS PER IFR APPROVAL √
RESPONSE
EFAVIRENZ NHS ENGLAND AIDS/HIV ANTIRETROVIRALS AGREED REGIONALGUIDELINES BHIVA GUIDELINES (8) BHIVA GUIDELINES (8) HARS DATASET √
RETROVIRAL DRUGS
EFRALOCTOCOG ALFA /
EFMOROCTOCOG ALFA / FACTOR HAEMOPHILIA A NHS ENGLAND BLOOD-RELATED PRODUCTS SSC 1652, see also SSC 1818 SSC 1652 SSC 1652 PRODUCTS ON CMU FRAMEWORK √
VIII FC FUSION PROTEIN (Elocta®)
EFTRENONACOG ALFA HAEMOPHILIA B NHS ENGLAND BLOOD-RELATED PRODUCTS SSC 1652 SSC 1652 SSC 1652 PRODUCTS ON CMU FRAMEWORK √

ELBASVIR HEPATITIS C NHS ENGLAND TA 413 AS PER RUN RATE CARD AS PER RUN RATE CARD HEPATITIS C MDS √ √
ELIGLUSTAT GAUCHER'S DISEASE NHS ENGLAND HST5 NICE NICE HIGHLY SPECIALISED DATABASE √
DISORDERS
LYSOSOMAL STORAGE DISORDER MANAGED ACCESS MANAGED ACCESS
ELOSULFASE ALFA MUCOPOLYSACCHARIDOSIS IV TYPE A NHS ENGLAND NICE HST2 MANAGED ACCESS AGREEMENT √ √
DRUGS AGREEMENT AGREEMENT
ELTROMBOPAG ITP IN CHILDREN NHS ENGLAND PLATELET DISORDER DRUGS AS PER ADULT TA 293 NICE NICE NICE AUDIT √ √
ELVITEGRAVIR NHS ENGLAND AIDS/HIV ANTIRETROVIRALS AGREED REGIONALGUIDELINES NHS ENGLAND POLICY NHS ENGLAND POLICY HARS DATASET √
RETROVIRAL DRUGS
ELVUCITABINE NHS ENGLAND AIDS/HIV ANTIRETROVIRALS NOT ROUTINELY COMMISSIONED AS PER IFR APPROVAL AS PER IFR APPROVAL AS PER IFR APPROVAL √
RETROVIRAL DRUGS
HAEMOPHAGOCYTIC
EMAPALUMAB NHS ENGLAND IMMUNOMODULATING DRUGS NOT ROUTINELY COMMISSIONED AS PER IFR APPROVAL AS PER IFR APPROVAL AS PER IFR APPROVAL √
LYMPHOHISTIOCYTOSIS
EMICIZUMAB NHS ENGLAND BLOOD-RELATED PRODUCTS COMMISSIONING POLICY: 170067/P AND NHS ENGLAND POLICY NHS ENGLAND POLICY PRODUCTS ON CMU FRAMEWORK √
170134P
NON-ALCOHOLIC STEATOHEPATITIS DRUGS USED IN METABOLIC
EMRICASAN NHS ENGLAND NOT ROUTINELY COMMISSIONED AS PER IFR APPROVAL AS PER IFR APPROVAL AS PER IFR APPROVAL √
(NASH) FIBROSIS DISORDERS
EMTRICITABINE NHS ENGLAND AIDS/HIV ANTIRETROVIRALS AGREED REGIONALGUIDELINES BHIVA GUIDELINES (8) BHIVA GUIDELINES (8) HARS DATASET √
RETROVIRAL DRUGS
EMTRICITABINE +TENOFOVIR + HIV IN COMBINATION WITH OTHER ANTI- NHS ENGLAND CLINICAL
NHS ENGLAND AIDS/HIV ANTIRETROVIRALS NHS ENGLAND POLICY NHS ENGLAND POLICY HARS DATASET √
DARUNAVIR + COBICISTAT RETROVIRAL DRUGS COMMISSIONING POLICY: F03/P/a
EMTRICITABINE +TENOFOVIR + HIV IN COMBINATION WITH OTHER ANTI- NHS ENGLAND CLINICAL
ELVITEGRAVIR + COBICISTAT RETROVIRAL DRUGS COMMISSIONING POLICY: F03/P/a
EMTRICITABINE +TENOFOVIR NHS ENGLAND AIDS/HIV ANTIRETROVIRALS AGREED REGIONALGUIDELINES BHIVA GUIDELINES (8) BHIVA GUIDELINES (8) HARS DATASET √
RETROVIRAL DRUGS
EMTRICITABINE + TENOFOVIR HIV IN COMBINATION WITH OTHER ANTI- NHS ENGLAND CLINICAL
ALAFENAMIDE RETROVIRAL DRUGS COMMISSIONING POLICY: 16043/P
EMTRICITABINE + RILPIVIRINE + HIV IN COMBINATION WITH OTHER ANTI- NHS ENGLAND CLINICAL
TENOFOVIR ALAFENAMIDE RETROVIRAL DRUGS COMMISSIONING POLICY: 16043/P
ENFUVIRTIDE NHS ENGLAND AIDS/HIV ANTIRETROVIRALS AGREED REGIONALGUIDELINES BHIVA GUIDELINES (8) BHIVA GUIDELINES (8) HARS DATASET √
RETROVIRAL DRUGS
ENTECAVIR HEPATITIS B NHS ENGLAND TA153 & IN PROGRESS NICE NICE NICE AUDIT √
TA316, TA 377 (SEE ALSO SSC1439)
NICE/NHS ENGLAND POLICY NICE
ENZALUTAMIDE CANCER NHS ENGLAND HORMONE ANTAGONISTS BOTH: ONLY IN ABIRATERONE NAÏVE SACT √
PATIENTS
DRUGS USED IN HYPOPLASTIC, RENAL DIALYSIS ONLY, INCLUDING VIA
EPOETIN ALPHA, BETA, THETA AND PRODUCT WITH LOWEST
DIALYSIS-INDUCED ANAEMIA NHS ENGLAND HAEMOLYTIC, AND RENAL ANAEMIAS - OUTPATIENTS, AND ONLY AS PER NICE TRUST GUIDELINES TRUST GUIDELINES √
ZETA PROCUREMENT COST TO BE USED
IRON OVERLOAD CG114
EPOPROSTENOL (5) PULMONARY ARTERIAL HYPERTENSION NHS ENGLAND DRUGS/PULMANORY ARTERIAL NHS ENGLAND POLICY NHS ENGLAND POLICY AS PER POLICY √
HYPERTENSION
EPRATUZUMAB SLE NHS ENGLAND CYTOKINE MODULATORS NOT ROUTINELY COMMISSIONED AS PER IFR APPROVAL AS PER IFR APPROVAL AS PER IFR APPROVAL √
EPRODISATE AMYLOIDOSIS NHS ENGLAND BLOOD-RELATED PRODUCTS NOT ROUTINELY COMMISSIONED AS PER IFR APPROVAL AS PER IFR APPROVAL AS PER IFR APPROVAL √
EPTOTERMIN ALFA COMPLEX SPINAL SURGERY NHS ENGLAND BONE MORPHOGENETIC PROTEIN NOT ROUTINELY COMMISSIONED AS PER IFR APPROVAL AS PER IFR APPROVAL AS PER IFR APPROVAL √
TA162, TA227, TA 374& IN PROGRESS
ERLOTINIB CANCER NHS ENGLAND PROTEIN KINASE INHIBITORS NICE NICE SACT √
NHSE LETTER

ETANERCEPT JUVENILE ARTHRITIS-PAEDIATRIC NHS ENGLAND CYTOKINE MODULATORS NHS ENGLAND POLICY NHS ENGLAND POLICY NHS ENGLAND POLICY √ √
ETANERCEPT PLAQUE PSORIASIS IN CHILDREN NHS ENGLAND CYTOKINE MODULATORS TA455 NICE NICE NICE AUDIT √ √
HYPERPARATHYROIDISM - DIALYSIS DRUGS FOR MINERAL BONE

ETELCALCETIDE NHS ENGLAND TA448 NICE NICE √ √
PATIENTS ONLY DISORDERS
ETEPLIRSEN DUCHENNE MUSCULAR DYSTROPHY NHS ENGLAND NEUROMUSCULAR DISORDERS NOT ROUTINELY COMMISSIONED AS PER IFR APPROVAL AS PER IFR APPROVAL AS PER IFR APPROVAL √

ETRAVIRINE NHS ENGLAND AIDS/HIV ANTIRETROVIRALS AGREED REGIONALGUIDELINES BHIVA GUIDELINES (8) BHIVA GUIDELINES (8) HARS DATASET √
RETROVIRAL DRUGS
EVEROLIMUS (AFINITOR®) CANCER NHS ENGLAND PROTEIN KINASE INHIBITORS TA421, TA432, TA449, TA498 NICE NICE SACT √ √
PREVENTING ORGAN REJECTION IN NOT ROUTINELY COMMISSIONED
EVEROLIMUS (CERTICAN®) NHS ENGLAND PROTEIN KINASE INHIBITORS AS PER IFR APPROVAL AS PER IFR APPROVAL AS PER IFR APPROVAL √
LIVER TRANSPLANTATION (TA348)
PREVENTING ORGAN REJECTION IN NOT ROUTINELY COMMISSIONED NHS
EVEROLIMUS (CERTICAN®) NHS ENGLAND PROTEIN KINASE INHIBITORS AS PER IFR APPROVAL AS PER IFR APPROVAL AS PER IFR APPROVAL √
HEART TRANSPLANTATION ENGLAND POLICY 16016/P
SUBEPENDYMAL GIANT CELL
EVEROLIMUS (VOTUBIA®) ASTROCYTOMA (SEGA) ASSOCIATED NHS ENGLAND PROTEIN KINASE INHIBITORS NHS ENGLAND POLICY NHS ENGLAND POLICY NHS ENGLAND POLICY √ √
WITH TUBULAR SCLEROSIS
SUITABLE FOR
SUITABLE FOR
SHARED CARE
CENTRE ONLY BETWEEN
PRIOR WITH PRIMARY
APPROVAL CARE (IF
REQUIRED LOCAL
PRESCRIBING
network) NETWORK
COMMITTEE)
MODEL
SEIZURES ASSOCIATED WITH
SUBEPENDYMAL GIANT CELL NHS ENGLAND CLINICAL
EVEROLIMUS (VOTUBIA®) NHS ENGLAND PROTEIN KINASE INHIBITORS NHS ENGLAND POLICY NHS ENGLAND POLICY NHS ENGLAND POLICY √ √
ASTROCYTOMA (SEGA) ASSOCIATED COMMISSIONING POLICY: 170093P
RENAL ANGIOMYOLIPOMA ASSOCIATED
EVEROLIMUS (VOTUBIA®) NHS ENGLAND PROTEIN KINASE INHIBITORS COMMISSIONING POLICY STATEMENT NHS ENGLAND POLICY NHS ENGLAND POLICY NHS ENGLAND POLICY √ √
B14X09L
HOMOZYGOUS FAMILIAL
EVINACUMAB NHS ENGLAND LIPID-REGULATING DRUGS NOT ROUTINELY COMMISSIONED AS PER IFR APPROVAL AS PER IFR APPROVAL AS PER IFR APPROVAL √
HYPERCHOLESTEROLAEMIA
AS NICE TA 394
HOMOZYGOUS FAMILIAL
EVOLOCUMAB NHS ENGLAND LIPID-REGULATING DRUGS (FOLLOW GUIDANCE FOR NICE NICE NICE AUDIT √
HYPERCHOLESTEROLAEMIA
HETEROZYGOUS FH)
TREATMENT OF ADULT PATIENTS WITH

EX-VIVO EXPANDED AUTOLOGOUS
MODERATE TO SEVERE LIMBAL STEM
HUMAN CORNEAL EPITHELIAL
CELL DEFICIENCY (LSCD), UNILATERAL NHS ENGLAND ATMP TA 467 NICE NICE NICE AUDIT √ √
CELLS CONTAINING STEM CELLS
OR BILATERAL, DUE TO PHYSICAL OR
(HOLOCLAR)
CHEMICAL OCULAR BURNS

FACTOR IX NHS ENGLAND BLOOD-RELATED PRODUCTS BCSH GUIDELINES BCSH GUIDELINES BCSH GUIDELINES PRODUCTS ON CMU FRAMEWORK √
FACTOR VII NHS ENGLAND BLOOD-RELATED PRODUCTS BCSH GUIDELINES BCSH GUIDELINES BCSH GUIDELINES √
FACTOR VIIA NHS ENGLAND BLOOD-RELATED PRODUCTS BCSH GUIDELINES BCSH GUIDELINES BCSH GUIDELINES PRODUCTS ON CMU FRAMEWORK √
FACTOR VIII NHS ENGLAND BLOOD-RELATED PRODUCTS BCSH GUIDELINES, see also SSC 1818 BCSH GUIDELINES BCSH GUIDELINES PRODUCTS ON CMU FRAMEWORK √
FACTOR VIII INHIBITOR BYPASSING AS PER BCSH GUIDELINES FOR
NHS ENGLAND BLOOD-RELATED PRODUCTS BCSH GUIDELINES BCSH GUIDELINES BCSH GUIDELINES PRODUCTS ON CMU FRAMEWORK √
FACTOR (FEIBA) SPECIALISED INDICATIONS
FACTOR XIII NHS ENGLAND BLOOD-RELATED PRODUCTS BCSH GUIDELINES BCSH GUIDELINES BCSH GUIDELINES PRODUCTS ON CMU FRAMEWORK √
FAMPRIDINE MULTIPLE SCLEROSIS NHS ENGLAND NEUROMUSCULAR DISORDERS AS PER IFR APPROVAL AS PER IFR APPROVAL AS PER IFR APPROVAL √****
NHS ENGLAND POLICY: 16010/P
FEDRATINIB MYELOFIBROSIS NHS ENGLAND NOT ROUTINELY COMMISSIONED AS PER IFR APPROVAL AS PER IFR APPROVAL AS PER IFR APPROVAL √
RESPONSE
FENFLURAMINE DRAVET DISEASE NHS ENGLAND CENTRAL NERVOUS SYSTEM NOT ROUTINELY COMMISSIONED AS PER IFR APPROVAL AS PER IFR APPROVAL AS PER IFR APPROVAL √

FIBRINOGEN NHS ENGLAND BLOOD-RELATED PRODUCTS BCSH GUIDELINES BCSH GUIDELINES BCSH GUIDELINES √
FIBROBLAST GROWTH FACTOR 1
SOMATOSTATIN ANALOGUE NHS ENGLAND SOMATOSTATIN ANALOGUES NOT ROUTINELY COMMISSIONED AS PER IFR APPROVAL AS PER IFR APPROVAL AS PER IFR APPROVAL √
GENE THERAPY
TA254
FINGOLIMOD MULTIPLE SCLEROSIS NHS ENGLAND IMMUNOMODULATING DRUGS NHS ENGLAND POLICY NHS ENGLAND POLICY NICE AUDIT √ √****
NHS ENGLAND POLICY: D04/P/b
ANAEMIAS AND SOME OTHER BLOOD
FITUSIRAN HAEMOPHILIA A AND B NHS ENGLAND NOT ROUTINELY COMMISSIONED AS PER IFR APPROVAL AS PER IFR APPROVAL AS PER IFR APPROVAL √
DISORDERS
FORIGERIMOD ACETATE SLE NHS ENGLAND CYTOKINE MODULATORS NOT ROUTINELY COMMISSIONED AS PER IFR APPROVAL AS PER IFR APPROVAL AS PER IFR APPROVAL √
FOSAMPRENAVIR NHS ENGLAND AIDS/HIV ANTIRETROVIRALS AGREED REGIONALGUIDELINES BHIVA GUIDELINES (8) BHIVA GUIDELINES (8) HARS DATASET √
RETROVIRAL DRUGS
FOSCARNET CYTOMEGALOVIRUS NHS ENGLAND CYTOMEGALOVIRUS INFECTION AGREED TRUST GUIDELINES TRUST GUIDELINES TRUST GUIDELINES PROPORTION GIVEN FOR SPC √
HIV iN COMBINATION WITH OTHER ANTI-
FOSTEMSAVIR NHS ENGLAND AIDS/HIV ANTIRETROVIRALS NOT ROUTINELY COMMISSIONED AS PER IFR APPROVAL AS PER IFR APPROVAL AS PER IFR APPROVAL √
RETROVIRAL DRUGS
GALUNISERTIB CANCER NHS ENGLAND MYELODYSPLASTIC SYNDROME NOT ROUTINELY COMMISSIONED AS PER IFR APPROVAL AS PER IFR APPROVAL AS PER IFR APPROVAL √
GALSULFASE MUCOPOLYSACCHARIDOSIS NHS ENGLAND NHS ENGLAND SERVICE SPECIFICATION HIGHLY SPECIALISED DATABASE √
GANCICLOVIR CYTOMEGALOVIRUS NHS ENGLAND CYTOMEGALOVIRUS INFECTION AGREED TRUST GUIDELINES TRUST GUIDELINES TRUST GUIDELINES PROPORTION GIVEN FOR SPC √
GANETESPIB CANCER NHS ENGLAND NOT ROUTINELY COMMISSIONED AS PER IFR APPROVAL AS PER IFR APPROVAL SACT √
RESPONSE
GEFITINIB CANCER NHS ENGLAND PROTEIN KINASE INHIBITORS TA192 NICE NICE SACT √
GEVOKIZUMAB UVEITIS NHS ENGLAND CYTOKINE MODULATORS NOT ROUTINELY COMMISSIONED AS PER IFR APPROVAL AS PER IFR APPROVAL AS PER IFR APPROVAL √
GIVOSIRAN HEPATIC PORPHYRIA NHS ENGLAND NOT ROUTINELY COMMISSIONED AS PER IFR APPROVAL AS PER IFR APPROVAL AS PER IFR APPROVAL √
DISORDERS
GLATIRAMER MULTIPLE SCLEROSIS NHS ENGLAND IMMUNOMODULATING DRUGS TA527 & NHS ENGLAND POLICY: D04/P/b NHS ENGLAND POLICY NHS ENGLAND POLICY AS PER NHSE POLICY √ √****

GLECAPREVIR HEPATITIS C NHS ENGLAND NICE TA 499 AS PER RUN RATE CARD AS PER RUN RATE CARD HEPATITIS C MDS √ √
METHOTREXATE INDUCED RENAL NHS ENGLAND CLINICAL
GLUCARPIDASE NHS ENGLAND POISONING NHS ENGLAND POLICY NHS ENGLAND POLICY NHS ENGLAND POLICY √
DYSFUNCTION COMMISSIONING POLICY: B15/P/a
DRUGS USED IN METABOLIC AS PER NHS ENGLAND CIRCULAR SSC
GLYCEROL PHENYLBUTYRATE UREA CYCLE DISORDERS NHS ENGLAND NHS ENGLAND POLICY NHS ENGLAND POLICY NHS ENGLAND POLICY √
DISORDERS 1881 AND LETTER
GOSURANEMAB SUPRANUCLEAR PALSY NHS ENGLAND CENTRAL NERVOUS SYSTEM NOT ROUTINELY COMMISSIONED AS PER IFR APPROVAL AS PER IFR APPROVAL AS PER IFR APPROVAL √
GRANULOCYTE-MACROPHAGE
ANTIBODY-POSITIVE PULMONARY
COLONY-STIMULATING FACTOR NHS ENGLAND DRUGS USED IN NEUTROPENIA NOT ROUTINELY COMMISSIONED AS PER IFR APPROVAL AS PER IFR APPROVAL AS PER IFR APPROVAL √
ALVEOLAR PROTEINOSIS
(LEUKINE® - IMPORT)
GRAZOPREVIR HEPATITIS C NHS ENGLAND TA 413 AS PER RUN RATE CARD AS PER RUN RATE CARD HEPATITIS C MDS √ √
HIV VACCINE HIV INFECTION PROPHYLAXIS NHS ENGLAND VACCINES AND ANTISERA NOT ROUTINELY COMMISSIONED AS PER IFR APPROVAL AS PER IFR APPROVAL AS PER IFR APPROVAL √
HAEM ARGINATE HEPATIC PORPHYRIA NHS ENGLAND NHS ENGLAND SERVICE SPECIFICATION HIGHLY SPECIALISED DATABASE √
HUMAN ALPHA-1 PROTEINASE
EMPHYSEMA NHS ENGLAND DRUGS USED FOR EMPHYSEMA NOT ROUTINELY COMMISSIONED AS PER IFR APPROVAL AS PER IFR APPROVAL AS PER IFR APPROVAL √
INHIBITOR
HUMAN COAGULATION FACTOR X FACTOR X DEFICIENCY NHS ENGLAND BLOOD-RELATED PRODUCTS NHS ENGLAND POLICY NHS ENGLAND POLICY AS PER POLICY √
COMMISSIONING POLICY:200208P
HUMAN HETEROLOGOUS LIVER DRUGS USED IN METABOLIC
UREA CYCLE DISORDERS NHS ENGLAND NOT ROUTINELY COMMISSIONED AS PER IFR APPROVAL AS PER IFR APPROVAL AS PER IFR APPROVAL √
CELLS DISORDERS
HUMAN PARATHYROID HORMONE- MALE AND JUVENILE OSTEOPOROSIS DRUGS AFFECTING BONE
RELATED PROTEIN ANALOGUE HYPOPARATHYROIDISM METABOLISM
HIV iN COMBINATION WITH OTHER ANTI-

IBALIZUMAB NHS ENGLAND AIDS/HIV ANTIRETROVIRALS NOT ROUTINELY COMMISSIONED AS PER IFR APPROVAL AS PER IFR APPROVAL AS PER IFR APPROVAL √
RETROVIRAL DRUGS
ICATIBANT NHS ENGLAND ALLERGIC EMERGENCIES NHS ENGLAND POLICY NHS ENGLAND POLICY AS PER POLICY √
TREATMENT ONLY COMMISSIONING POLICY: B09/P/b
HEREDUTARY ANGIOEDEMA - NHS ENGLAND CLINICAL
ICATIBANT NHS ENGLAND ALLERGIC EMERGENCIES NHS ENGLAND POLICY NHS ENGLAND POLICY AS PER POLICY √ √
PROPHYLACTIC TREATMENT COMMISSIONING POLICY: 16045/P
IDEBENONE DUCHENNE MUSCULAR DYSTROPHY NHS ENGLAND NEUROMUSCULAR DISORDERS NOT ROUTINELY COMMISSIONED AS PER IFR APPROVAL AS PER IFR APPROVAL AS PER IFR APPROVAL √

IDURSULFASE MUCOPOLYSACCHARIDOSIS NHS ENGLAND NHS ENGLAND SERVICE SPECIFICATION HIGHLY SPECIALISED DATABASE √
SUITABLE FOR
SUITABLE FOR
SHARED CARE
CENTRE ONLY BETWEEN
PRIOR WITH PRIMARY
APPROVAL CARE (IF
REQUIRED LOCAL
PRESCRIBING
network) NETWORK
COMMITTEE)
MODEL
ILOPROST (5) PULMONARY ARTERIAL HYPERTENSION NHS ENGLAND DRUGS/PULMANORY ARTERIAL NHS ENGLAND POLICY NHS ENGLAND POLICY AS PER POLICY √
HYPERTENSION
IMATINIB CANCER NHS ENGLAND PROTEIN KINASE INHIBITORS TA70, TA86, TA251, TA326 NICE NICE SACT √
CHRONIC GRAFT VERSUS HOST NHS ENGLAND CLINICAL

IMATINIB NHS ENGLAND CYTOKINE MODULATORS NHS ENGLAND POLICY NHS ENGLAND POLICY NHS ENGLAND POLICY √
DISEASE COMMISSIONING POLICY:16069/P
IMETELSTAT CANCER NHS ENGLAND PROTEIN KINASE INHIBITORS NOT ROUTINELY COMMISSIONED AS PER IFR APPROVAL AS PER IFR APPROVAL AS PER IFR APPROVAL √
IMIGLUCERASE GAUCHER'S DISEASE NHS ENGLAND NHS ENGLAND SERVICE SPECIFICATION HIGHLY SPECIALISED DATABASE √
TRANSPLANT REJECTION PREVENTION
IMLIFIDASE NHS ENGLAND NO GROUP NAME AGREED NOT ROUTINELY COMMISSIONED AS PER IFR APPROVAL AS PER IFR APPROVAL AS PER IFR APPROVAL √
IN HLA-SENSITISED PATIENTS
INDINAVIR NHS ENGLAND AIDS/HIV ANTIRETROVIRALS AGREED REGIONALGUIDELINES BHIVA GUIDELINES (8) BHIVA GUIDELINES (8) HARS DATASET √
RETROVIRAL DRUGS
INEBILIZUMAB MULTIPLE SCLEROSIS NHS ENGLAND IMMUNOMODULATING DRUGS NOT ROUTINELY COMMISSIONED AS PER IFR APPROVAL AS PER IFR APPROVAL AS PER IFR APPROVAL √
INFLIXIMAB JUVENILE ARTHRITIS-PAEDIATRIC NHS ENGLAND CYTOKINE MODULATORS NHS ENGLAND POLICY NHS ENGLAND POLICY NHS ENGLAND POLICY √ √
(NHS ENGLAND CLINICAL
INFLIXIMAB UVEITIS NHS ENGLAND CYTOKINE MODULATORS AS PER IFR APPROVAL AS PER IFR APPROVAL AS PER IFR APPROVAL √
COMMISSIONING POLICY: D12/P/a &
D12/P/a)
CONNECTIVE TISSUE DISEASE - NOT ROUTINELY COMMISSIONED -
INFLIXIMAB NHS ENGLAND CYTOKINE MODULATORS AS PER IFR APPROVAL AS PER IFR APPROVAL AS PER IFR APPROVAL √
INTERSTITAL LUNG DISEASE POLICY IN PROGRESS
INFLIXIMAB CROHN'S DISEASE IN CHILDREN NHS ENGLAND CYTOKINE MODULATORS TA187 NICE NICE NICE AUDIT √
INFLIXIMAB GRAFT VERSUS HOST DISEASE NHS ENGLAND CYTOKINE MODULATORS NOT ROUTINELY COMMISSIONED AS PER IFR APPROVAL AS PER IFR APPROVAL AS PER IFR APPROVAL √
INFLIXIMAB RENAL NHS ENGLAND CYTOKINE MODULATORS NOT ROUTINELY COMMISSIONED AS PER IFR APPROVAL AS PER IFR APPROVAL AS PER IFR APPROVAL √
INFLIXIMAB PULMONARY SARCOIDOSIS NHS ENGLAND CYTOKINE MODULATORS AS PER IFR APPROVAL AS PER IFR APPROVAL AS PER IFR APPROVAL √
NHS ENGAND POLICY 170088P
NOT ROUTINELY COMMISSIONED - NHS
INFLIXIMAB HIDRADENITIS SUPPURATIVA NHS ENGLAND CYTOKINE MODULATORS AS PER IFR APPROVAL AS PER IFR APPROVAL AS PER IFR APPROVAL √
ENGLAND POLICY 16018/P
INFLIXIMAB BEHCETS SYNDROME NHS ENGLAND CYTOKINE MODULATORS HIGHLY SPECIALISED CRITERIA ONLY HIGHLY SPECIALISED CRITERIA √
INOTERSEN AMYLOIDOSIS NHS ENGLAND UNCLASSIFIED HST9 NICE NICE NICE AUDIT √ √
INTERFERON ALFA HEPATITIS B AND C NHS ENGLAND IMMUNOMODULATING DRUGS TA75 NICE NICE NICE AUDIT √
MIDDLE EAST RESPIRATORY
INTERFERON ALFA N3 IMMUNOMODULATING DRUGS NOT ROUTINELY COMMISSIONED AS PER IFR APPROVAL AS PER IFR APPROVAL AS PER IFR APPROVAL √
SYNDROME
TA 527, TA624
INTERFERON BETA MULTIPLE SCLEROSIS NHS ENGLAND IMMUNOMODULATING DRUGS NHS ENGLAND POLICY NHS ENGLAND POLICY AS PER NHSE POLICY √ √****
CLINICAL GUIDELINES FOR

IMMUNOGLOBULIN USE, SECOND
EDITION UPDATE (JULY 2011) QUALITY DASHBOARD
INTRAVENOUS NORMAL HUMAN INTRAVENOUS NORMAL HUMAN
MULTIPLE INDICATIONS NHS ENGLAND IMMUNOGLOBULIN GUIDELINES NATIONAL GUIDELINES NATIONAL GUIDELINES NATIONAL IMMUNOGLOBULIN DATA √
IMMUNOGLOBULINS IMMUNOGLOBULINS
PUBLISHED 2019 ON MDSAS WEBSITE BASE

FUNGAL INFECTION (LICENSED
ISAVUCONAZOLE NHS ENGLAND ANTIFUNGALS AGREED TRUST GUIDELINES TRUST GUIDELINES TRUST GUIDELINES PROPORTION GIVEN FOR SPC √ √
INDICATIONS)
IVACAFTOR CYSTIC FIBROSIS NHS ENGLAND MUCOLYTICS COMMISSIONING POLICY: A01/P/c, NHS ENGLAND POLICY NHS ENGLAND POLICY NHS ENGLAND POLICY √
16049/P
IXAZOMIB AMYLOIDOSIS NHS ENGLAND CANCER EXCLUSION NOT ROUTINELY COMMISSIONED AS PER IFR APPROVAL AS PER IFR APPROVAL AS PER IFR APPROVAL √
IXAZOMIB MULTIPLE MYELOMA CDF CANCER EXCLUSION CDF (TA 505) CDF CDF SACT √ √
LAMIVUDINE HEPATITIS B NHS ENGLAND CG165 NICE NICE NICE AUDIT √
LAMIVUDINE NHS ENGLAND AIDS/HIV ANTIRETROVIRALS AGREED REGIONALGUIDELINES BHIVA GUIDELINES (8) BHIVA GUIDELINES (8) HARS DATASET √
RETROVIRAL DRUGS
LANADELUMAB HEREDITARY ANGIOEDEMA NHS ENGLAND ALLERGIC EMERGENCIES TA606 NICE NICE NICE AUDIT √ √
PRODUCT WITH LOWEST

LANREOTIDE CANCER NHS ENGLAND SOMATOSTATIN ANALOGUES AGREED TRUST GUIDELINES TRUST GUIDELINES TRUST GUIDELINES √

LANREOTIDE CONGENITAL HYPERINSULINISM NHS ENGLAND SOMATOSTATIN ANALOGUES HIGHLY SPECIALISED CRITERIA ONLY √
PRODUCT WITH LOWEST

LANREOTIDE*** ACROMEGALY NHS ENGLAND SOMATOSTATIN ANALOGUES AGREED TRUST GUIDELINES TRUST GUIDELINES TRUST GUIDELINES √ √
LANTHANUM CARBONATE ADULT RENAL DIALYSIS ONLY NHS ENGLAND PHOSPHATE BINDING AGENTS TRUST GUIDELINES TRUST GUIDELINES √
LAPATINIB CANCER NHS ENGLAND PROTEIN KINASE INHIBITORS NOT ROUTINELY COMMISSIONED AS PER IFR APPROVAL AS PER IFR APPROVAL SACT √
LAQUINIMOD MULTIPLE SCLEROSIS NHS ENGLAND IMMUNOMODULATING DRUGS NOT ROUTINELY COMMISSIONED AS PER IFR APPROVAL AS PER IFR APPROVAL AS PER IFR APPROVAL √****
LARONIDASE MUCOPOLYSACCHARIDOSIS NHS ENGLAND NHS ENGLAND SERVICE SPECIFICATION HIGHLY SPECIALISED DATABASE √
LEBRIKIZUMAB ASTHMA NHS ENGLAND ALLERGEN IMMUNOTHERAPY NOT ROUTINELY COMMISSIONED AS PER IFR APPROVAL AS PER IFR APPROVAL AS PER IFR APPROVAL √
LENALIDOMIDE CANCER NHS ENGLAND IMMUNOMODULATING DRUGS TA171, TA322, TA587, TA586 NICE NICE SACT √ √

LENALIDOMIDE POEMS NHS ENGLAND IMMUNOMODULATING DRUGS HIGHLY SPECIALISED CRITERIA ONLY √
LERONLIMAB NHS ENGLAND AIDS/HIV ANTIRETROVIRALS NOT ROUTINELY COMMISSIONED AS PER IFR APPROVAL AS PER IFR APPROVAL AS PER IFR APPROVAL √
RETROVIRAL DRUGS
LETERMOVIR CYTOMEGALOVIRUS NHS ENGLAND CYTOMEGALOVIRUS INFECTION TA 591 NICE NICE NICE AUDIT √ √
LEVOFLOXACIN (INHALED) CYSTIC FIBROSIS NHS ENGLAND ANTIBACTERIAL DRUGS NHS ENGLAND POLICY 170078P NHS ENGLAND POLICY NHS ENGLAND POLICY NHS ENGLAND POLICY √
LEVOKETOCONAZOLE CUSHING'S DISEASE NHS ENGLAND NOVEL - NO GROUP NAME AGREED NOT ROUTINELY COMMISSIONED AS PER IFR APPROVAL AS PER IFR APPROVAL AS PER IFR APPROVAL √
HYPONATRAEMIA AND OTHER POSTERIOR PITUITARY HORMONES
LIXIVAPTAN NHS ENGLAND NOT ROUTINELY COMMISSIONED AS PER IFR APPROVAL AS PER IFR APPROVAL AS PER IFR APPROVAL √
ENDOCRINE USES AND ANTAGONISTS
HOMOZYGOUS FAMILIAL
LOMITAPIDE NHS ENGLAND LIPID-REGULATING DRUGS NHS ENGLAND POLICY 170059P NHS ENGLAND POLICY NHS ENGLAND POLICY NHS ENGLAND POLICY √
HYPERCHOLESTEROLEMIA
LONAFARNIB CANCER NHS ENGLAND PROTEIN KINASE INHIBITORS NOT ROUTINELY COMMISSIONED AS PER IFR APPROVAL AS PER IFR APPROVAL AS PER IFR APPROVAL √
LOPINAVIR + RITONAVIR NHS ENGLAND AIDS/HIV ANTIRETROVIRALS AGREED REGIONALGUIDELINES BHIVA GUIDELINES (8) BHIVA GUIDELINES (8) HARS DATASET √
RETROVIRAL DRUGS
NHS ENGLAND URGENT POLICY
LUMACAFTOR AND IVACAFTOR CYSTIC FIBROSIS NHS ENGLAND MUCOLYTICS NHS ENGLAND POLICY NHS ENGLAND POLICY AS PER POLICY √
STATEMENT 190137P
LUSPATERCEPT CANCER NHS ENGLAND MYELODYSPLASTIC SYNDROME NOT ROUTINELY COMMISSIONED AS PER IFR APPROVAL AS PER IFR APPROVAL AS PER IFR APPROVAL √
GROWTH HORMONE & GROWTH

MACIMORELIN GROWTH FAILURE NHS ENGLAND NOT ROUTINELY COMMISSIONED AS PER IFR APPROVAL AS PER IFR APPROVAL AS PER IFR APPROVAL √
MACITENTAN PULMONARY ARTERIAL HYPERTENSION NHS ENGLAND DRUGS/PULMANORY ARTERIAL NHS ENGLAND POLICY NHS ENGLAND POLICY AS PER POLICY √
HYPERTENSION
MANNITOL CYSTIC FIBROSIS NHS ENGLAND MUCOLYTICS COMMISSIONING POLICY: A01/P/b √
TA266
MARALIXIBAT ALAGILLE SYNDROME NHS ENGLAND NOVEL - NO GROUP NAME AGREED NOT ROUTINELY COMMISSIONED AS PER IFR APPROVAL AS PER IFR APPROVAL AS PER IFR APPROVAL √
SUITABLE FOR
SUITABLE FOR
SHARED CARE
CENTRE ONLY BETWEEN
PRIOR WITH PRIMARY
APPROVAL CARE (IF
REQUIRED LOCAL
PRESCRIBING
network) NETWORK
COMMITTEE)
MODEL
MARAVIROC NHS ENGLAND AIDS/HIV ANTIRETROVIRALS AGREED REGIONALGUIDELINES BHIVA GUIDELINES (8) BHIVA GUIDELINES (8) HARS DATASET √
RETROVIRAL DRUGS
MARAVIROC NATALIZUMAB INDUCED PML NHS ENGLAND AIDS/HIV ANTIRETROVIRALS NHS ENGLAND POLICY STATEMENT AS PER IFR APPROVAL AS PER IFR APPROVAL AS PER IFR APPROVAL √
170040P
MARIBAVIR CYTOMEGALOVIRUS NHS ENGLAND CYTOMEGALOVIRUS INFECTION NOT ROUTINELY COMMISSIONED AS PER IFR APPROVAL AS PER IFR APPROVAL AS PER IFR APPROVAL √
MASITINIB PANCREATIC CANCER/GIST NHS ENGLAND PROTEIN KINASE INHIBITORS NOT ROUTINELY COMMISSIONED AS PER IFR APPROVAL AS PER IFR APPROVAL AS PER IFR APPROVAL √
GROWTH HORMONE & GROWTH NHS ENGLAND CLINICAL

MECASERMIN GROWTH FAILURE NHS ENGLAND NHS ENGLAND POLICY NHS ENGLAND POLICY AS PER POLICY √
HORMONE RECEPTOR ANTAGONIST COMMISSIONING POLICY: EO3/P/a
TA431
MEPOLIZUMAB ASTHMA NHS ENGLAND ALLERGEN IMMUNOTHERAPY NICE NICE NICE AUDIT √ √
METRELEPTIN DYSLIPIDAEMIA NHS ENGLAND OTHER ENDOCRINE DRUGS NOT ROUTINELY COMMISSIONED AS PER IFR APPROVAL AS PER IFR APPROVAL AS PER IFR APPROVAL √

METRELEPTIN CONGENITAL LEPTIN DEFICIENCY NHS ENGLAND OTHER ENDOCRINE DRUGS NHS ENGLAND POLICY NHS ENGLAND POLICY AS PER POLICY √
AS PER NHS ENGLAND CIRCULAR SSC
MEXILETINE NON DYSTROPHIC MYOTONIA NHS ENGLAND NEUROMUSCULAR DISORDERS AS PER BLUETEQ FORM AS PER BLUETEQ FORM AS PER BLUETEQ FORM √ √
2001 AND LETTER
MICAFUNGIN FUNGAL INFECTION NHS ENGLAND ANTIFUNGALS AGREED TRUST GUIDELINES TRUST GUIDELINES TRUST GUIDELINES PROPORTION GIVEN FOR SPC √
MIGALASTAT FABRY'S DISEASE NHS ENGLAND NICE HST4 NICE NICE HIGHLY SPECIALISED DATABASE √
DISORDERS
MIGLUSTAT GAUCHER'S DISEASE/ NIEMANN-PICK NHS ENGLAND NHS ENGLAND SERVICE SPECIFICATION HIGHLY SPECIALISED DATABASE √
MOMELOTINIB CANCER NHS ENGLAND PROTEIN KINASE INHIBITORS NOT ROUTINELY COMMISSIONED AS PER IFR APPROVAL AS PER IFR APPROVAL AS PER IFR APPROVAL √
TA127
NATALIZUMAB MULTIPLE SCLEROSIS NHS ENGLAND IMMUNOMODULATING DRUGS NHS ENGLAND POLICY NHS ENGLAND POLICY NICE AUDIT √ √****
NELFINAVIR NHS ENGLAND AIDS/HIV ANTIRETROVIRALS AGREED REGIONALGUIDELINES BHIVA GUIDELINES (8) BHIVA GUIDELINES (8) HARS DATASET √
RETROVIRAL DRUGS
NEVIRAPINE NHS ENGLAND AIDS/HIV ANTIRETROVIRALS AGREED REGIONALGUIDELINES BHIVA GUIDELINES (8) BHIVA GUIDELINES (8) HARS DATASET √
RETROVIRAL DRUGS
NILOTINIB CANCER NHS ENGLAND PROTEIN KINASE INHIBITORS TA241, TA251, TA426 NICE NICE SACT √ √
NINTEDANIB OVARIAN CANCER NHS ENGLAND IMMUNOMODULATING DRUGS NOT ROUTINELY COMMISSIONED AS PER IFR APPROVAL AS PER IFR APPROVAL SACT √
NINTEDANIB (OFEV®) IDIOPATHIC PULMONARY FIBROSIS NHS ENGLAND IMMUNOMODULATING DRUGS TA 379 NICE NICE NICE AUDIT √ √
NINTEDANIB (VARGATEF®) NON-SMALL-CELL LUNG CANCER NHS ENGLAND IMMUNOMODULATING DRUGS TA347 NICE NICE SACT √
NITAZOXANIDE HEPATITIS C NHS ENGLAND NOT ROUTINELY COMMISSIONED AS PER IFR APPROVAL AS PER IFR APPROVAL AS PER IFR APPROVAL √
NITISINONE ALKAPTONURIA NHS ENGLAND NHS ENGLAND SERVICE SPECIFICATION HIGHLY SPECIALISED DATABASE √
NITISINONE TYROSINAEMIA NHS ENGLAND NHS ENGLAND SERVICE SPECIFICATION HIGHLY SPECIALISED DATABASE √
NITRIC OXIDE PULMONARY ARTERIAL HYPERTENSION NHS ENGLAND DRUGS/PULMANORY ARTERIAL AGREED TRUST GUIDELINES TRUST GUIDELINES TRUST GUIDELINES √
HYPERTENSION
NUSINERSEN SPINAL MUSCULAR ATROPHY NHS ENGLAND NEURODEGENERATIVE CONDITIONS TA588 NICE NICE NICE AUDIT √ √

OBETICHOLIC ACID PRIMARY BILIARY CIRRHOSIS NHS ENGLAND TA443 NICE NICE NICE AUDIT √ √
DISORDERS
OCRELIZUMAB MULTIPLE SCLEROSIS NHS ENGLAND TA 533, TA 585 NICE NICE NICE AUDIT √ √****
RESPONSE
OCTOCOG ALFA HAEMOPHILIA A NHS ENGLAND BLOOD-RELATED PRODUCTS BCSH GUIDELINES: See also SSC 1818 AS PER IFR APPROVAL AS PER IFR APPROVAL AS PER IFR APPROVAL √
GROWTH HORMONE & GROWTH

OCTREOLIN ACROMEGALY NHS ENGLAND NOT ROUTINELY COMMISSIONED AS PER IFR APPROVAL AS PER IFR APPROVAL AS PER IFR APPROVAL √
PRODUCT WITH LOWEST

OCTREOTIDE CANCER NHS ENGLAND SOMATOSTATIN ANALOGUES AGREED TRUST GUIDELINES TRUST GUIDELINES TRUST GUIDELINES √

OCTREOTIDE CONGENITAL HYPERINSULINISM NHS ENGLAND SOMATOSTATIN ANALOGUES HIGHLY SPECIALISED CRITERIA ONLY √
PRODUCT WITH LOWEST

OCTREOTIDE*** ACROMEGALY NHS ENGLAND SOMATOSTATIN ANALOGUES AGREED TRUST GUIDELINES TRUST GUIDELINES TRUST GUIDELINES √
OLESOXIME SPINAL MUSCULAR ATROPHY NHS ENGLAND NEUROMUSCULAR DISORDERS NOT ROUTINELY COMMISSIONED AS PER IFR APPROVAL AS PER IFR APPROVAL AS PER IFR APPROVAL √
OLIPUDASE ALFA ACID SPHINGOMYELINASE DEFICIENCY NHS ENGLAND NOT ROUTINELY COMMISSIONED AS PER IFR APPROVAL AS PER IFR APPROVAL AS PER IFR APPROVAL √
DRUGS
OMALIZUMAB ASTHMA NHS ENGLAND ALLERGEN IMMUNOTHERAPY TA278 NICE NICE NICE AUDIT √ √
OMBITASVIR/PARITAPREVIR/RITON VIRAL HEPATITIS (B&C) &
HEPATITIS C NHS ENGLAND TA 365 AS PER RUN RATE CARD AS PER RUN RATE CARD HEPATITIS C MDS √ √
AVIR + DASABUVIR + RIBAVIRIN RESPIRATORY SYNCYTIAL VIRUS
OSILODROSTAT CUSHING'S DISEASE NHS ENGLAND OTHER ENDOCRINE DRUGS NOT ROUTINELY COMMISSIONED AS PER IFR APPROVAL AS PER IFR APPROVAL AS PER IFR APPROVAL √
OZANIMOD MULTIPLE SCLEROSIS NHS ENGLAND IMMUNOMODULATING DRUGS NOT ROUTINELY COMMISSIONED AS PER IFR APPROVAL AS PER IFR APPROVAL AS PER IFR APPROVAL √
PACRITINIB MYELOFIBROSIS NHS ENGLAND PROTEIN KINASE INHIBITORS NOT ROUTINELY COMMISSIONED AS PER IFR APPROVAL AS PER IFR APPROVAL AS PER IFR APPROVAL √
FYBRODYSPLASIA OSSIFICANS DRUGS AFFECTING BONE
PALOVAROTENE NHS ENGLAND NOT ROUTINELY COMMISSIONED AS PER IFR APPROVAL AS PER IFR APPROVAL AS PER IFR APPROVAL √
PROGRESSIVA METABOLISM
VIRAL HEPATITIS (B&C) & JCVI GUIDELINES
PALIVIZUMAB RSV PROPHYLAXIS NHS ENGLAND AS PER SPECIFICATION AS PER SPECIFICATION √ √
RESPIRATORY SYNCYTIAL VIRUS PHE SPECIFICATION
PARA-AMINOSALICYLIC ACID NHS ENGLAND CLINICAL
MULTI DRUG RESITANT TB NHS ENGLAND ANTITUBERCULOSIS DRUGS NHS ENGLAND POLICY NHS ENGLAND POLICY NHS ENGLAND POLICY √
SPECIALIST ENDOCRINOLOGY
PARATHYROID HORMONE NHS ENGLAND PARATHYROID HORMONE AGREED TRUST GUIDELINES TRUST GUIDELINES TRUST GUIDELINES √
CONDITIONS
PARENTERAL NUTRITION (HOME
INTESTINAL FAILURE NHS ENGLAND PARENTERAL NUTRITION AS PER BLUETEQ FORM AS PER BLUETEQ FORM AS PER BLUETEQ FORM AUDIT √ √
USE)
ONLY WHEN DURATION OF PN IS > 14

DAYS OR INITIATED PRIOR TO
PARENTERAL NUTRITION INTESTINAL FAILURE; INADEQUATE/
NHS ENGLAND PARENTERAL NUTRITION ADMISSION. ADULTS; SEE ALSO CG32. TRUST GUIDELINES TRUST GUIDELINES √
(INPATIENT USE) UNSAFE ENTERAL FEEDING
SEE ALSO 'MANUAL FOR PRESCRIBED
SPECIALISED SERVICES'
PARICALCITOL HYPERPARATHYROIDISM NHS ENGLAND OTHER ENDOCRINE DRUGS AS PER CINACALCET AS PER CINACALCET AS PER CINACALCET AS PER CINACALCET √
PARITAPREVIR HEPATITIS C NHS ENGLAND NICE TA 499 AS PER RUN RATE CARD AS PER RUN RATE CARD HEPATITIS C MDS √
PASIREOTIDE ACROMEGALY NHS ENGLAND SOMATOSTATIN ANALOGUES AS PER IFR APPROVAL AS PER IFR APPROVAL AS PER IFR APPROVAL √
PASIREOTIDE CUSHING'S DISEASE NHS ENGLAND SOMATOSTATIN ANALOGUES NHS ENGLAND POLICY NHS ENGLAND POLICY NHS ENGLAND POLICY √ √
COMMISSIONING POLICY: A03X03/01
PATISIRAN AMYLOIDOSIS NHS ENGLAND NOVEL - NO GROUP NAME AGREED HST10 NICE NICE NICE AUDIT √ √
TA215
PAZOPANIB CANCER NHS ENGLAND PROTEIN KINASE INHIBITORS NOT ROUTINELY COMMISSIONED NHS NICE NICE SACT √
ENGLAND POLICY STATEMENT 170117P
SUITABLE FOR
SUITABLE FOR
SHARED CARE
CENTRE ONLY BETWEEN
PRIOR WITH PRIMARY
APPROVAL CARE (IF
REQUIRED LOCAL
PRESCRIBING
network) NETWORK
COMMITTEE)
MODEL
VIRAL HEPATITIS (B&C) & COMMISSIONING POLICY: B07/P/a; TA75,
PEG INTERFERON ALFA HEPATITIS B AND C NHS ENGLAND NICE NICE NICE AUDIT √
RESPIRATORY SYNCYTIAL VIRUS TA96, TA106, TA200, TA 300
CG165
ROUTINELY COMMISSIONED AS PER

PEGINTERFERON BETA-1A MULTIPLE SCLEROSIS NHS ENGLAND IMMUNOMODULATING DRUGS SSC1534: MULTIPLE SCLEROSIS FIRST NHS ENGLAND POLICY NHS ENGLAND POLICY NICE AUDIT √ √****
LINE DISEASE MODIFYING AGENTS

PEGUNIGALSIDASE ALFA FABRY'S DISEASE NHS ENGLAND NOT ROUTINELY COMMISSIONED AS PER IFR APPROVAL AS PER IFR APPROVAL AS PER IFR APPROVAL √
DRUGS
PEGVALIASE PHENYLKETONURIA NHS ENGLAND NOT ROUTINELY COMMISSIONED AS PER IFR APPROVAL AS PER IFR APPROVAL AS PER IFR APPROVAL √
DISORDERS
HYPOTHALMIC & ANTERIOR PITUITARY NHS ENGLAND CLINICAL

PEGVISOMANT ACROMEGALY NHS ENGLAND NHS ENGLAND POLICY NHS ENGLAND POLICY NHS ENGLAND POLICY √
HORMONES & ANTI-OESTROGENS COMMISSIONING POLICY: 16050/P
TA 357, TA366, TA428, TA531

CDF POLICY (TA 447 (replaced by TA531), NICE NICE
PEMBROLIZUMAB CANCER INDICATIONS NHS ENGLAND/CDF CANCER EXCLUSION SACT √ √
TA 519, TA522 TA540, TA553, TA557 & CDF CDF
TA600)
DRUG RESISTANT GESTATIONAL
PEMBROLIZUMAB NHS ENGLAND CANCER EXCLUSION COMMISSIONING POLICY STATEMENT: NHS ENGLAND POLICY NHS ENGLAND POLICY NHS ENGLAND POLICY √
TROPHOBLASTIC NEOPLASIA
170027P
PIBRENTASVIR HEPATITIS C NHS ENGLAND TA499 AS PER RUN RATE CARD AS PER RUN RATE CARD HEPATITIS C MDS √
PIRFENIDONE IDIOPATHIC PULMONARY FIBROSIS NHS ENGLAND PULMONARY FIBROSIS TA 504 (SPECIALIST CENTRE ONLY) NICE NICE NICE AUDIT √ √
DRUGS AFFECTING THE IMMUNE NUMBER OF PATIENTS
PLERIXAFOR STEM CELL MOBILISATION NHS ENGLAND COMMISSIONING POLICY: B04/P/b, NHS ENGLAND POLICY NHS ENGLAND POLICY √ √
RESPONSE SUCCESSFULLY TRANSPLANTED
16064/P
STAGE DRUG UTILISED
POMALIDOMIDE CANCER NHS ENGLAND IMMUNOMODULATING DRUGS TA427 NICE NICE SACT √ √
POMALIDOMIDE MYELOFIBROSIS NHS ENGLAND IMMUNOMODULATING DRUGS NOT ROUTINELY COMMISSIONED AS PER IFR APPROVAL AS PER IFR APPROVAL AS PER IFR APPROVAL √
PONATINIB CANCER NHS ENGLAND PROTEIN KINASE INHIBITORS TA451 NICE NICE SACT √ √
DRUGS USED FOR NEUROMUSCULAR
PONESIMOD MULTIPLE SCLEROSIS NHS ENGLAND NOT ROUTINELY COMMISSIONED AS PER IFR APPROVAL AS PER IFR APPROVAL AS PER IFR APPROVAL √
DISORDERS
POSACONAZOLE FUNGAL INFECTION NHS ENGLAND ANTIFUNGALS AGREED TRUST GUIDELINES TRUST GUIDELINES TRUST GUIDELINES PROPORTION GIVEN FOR SPC √
PRETOMANID MULTI DRUG RESITANT TB NHS ENGLAND ANTITUBERCULOSIS DRUGS NOT ROUTINELY COMMISSIONED AS PER IFR APPROVAL AS PER IFR APPROVAL AS PER IFR APPROVAL √
PROTEIN C NHS ENGLAND BLOOD-RELATED PRODUCTS BCSH GUIDELINES BCSH GUIDELINES BCSH GUIDELINES PRODUCTS ON CMU FRAMEWORK √
PROTHROMBIN COMPLEX NHS ENGLAND BLOOD-RELATED PRODUCTS BCSH GUIDELINES BCSH GUIDELINES BCSH GUIDELINES PRODUCTS ON CMU FRAMEWORK √
RALTEGRAVIR NHS ENGLAND AIDS/HIV ANTIRETROVIRALS AGREED REGIONALGUIDELINES BHIVA GUIDELINES (8) BHIVA GUIDELINES (8) HARS DATASET √
RETROVIRAL DRUGS
GOUT AND CYTOTOXIC-INDUCED
RASBURICASE HYPERURICAEMIA NHS ENGLAND AGREED TRUST GUIDELINES TRUST GUIDELINES TRUST GUIDELINES √
HYPERURICAEMIA
PAROXYSMAL NOCTURNAL PAROXYSMAL NOCTURNAL
RAVULIZUMAB NHS ENGLAND NOT ROUTINELY COMMISSIONED AS PER IFR APPROVAL AS PER IFR APPROVAL AS PER IFR APPROVAL √
HAEMOGLOBINURIA HAEMOGLOBINURIA
RAXIBACUMAB INHALED ANTHRAX NHS ENGLAND NOVEL - NO GROUP NAME AGREED NOT ROUTINELY COMMISSIONED AS PER IFR APPROVAL AS PER IFR APPROVAL AS PER IFR APPROVAL √
PREVENTION OF DELAYED GRAFT
REFANALIN NHS ENGLAND NOVEL - NO GROUP NAME AGREED NOT ROUTINELY COMMISSIONED AS PER IFR APPROVAL AS PER IFR APPROVAL AS PER IFR APPROVAL √
FUNCTION
REGORAFENIB CANCER NHS ENGLAND PROTEIN KINASE INHIBITORS TA488 & TA555 NICE NICE SACT √ √
REPARIXIN NHS ENGLAND NOVEL - NO GROUP NAME AGREED NOT ROUTINELY COMMISSIONED AS PER IFR APPROVAL AS PER IFR APPROVAL AS PER IFR APPROVAL √
FUNCTION
RESLIZUMAB ASTHMA NHS ENGLAND ALLERGEN IMMUNOTHERAPY TA479 NICE NICE NICE AUDIT √ √
REVEGLUCOSIDASE ALFA POMPE DISEASE NHS ENGLAND NOT ROUTINELY COMMISSIONED AS PER IFR APPROVAL AS PER IFR APPROVAL AS PER IFR APPROVAL √
DRUGS
RISDIPLAM SPINAL MUSCULAR ATROPHY NHS ENGLAND NEURODEGENERATIVE CONDITIONS NOT ROUTINELY COMMISSIONED AS PER IFR APPROVAL AS PER IFR APPROVAL AS PER IFR APPROVAL √
RIGOSERTIB MDS/PANCREATIC CANCER NHS ENGLAND MYELODYSPLASTIC SYNDROME NOT ROUTINELY COMMISSIONED AS PER IFR APPROVAL AS PER IFR APPROVAL AS PER IFR APPROVAL √
RILPIVIRINE NHS ENGLAND AIDS/HIV ANTIRETROVIRALS AGREED REGIONALGUIDELINES BHIVA GUIDELINES (8) BHIVA GUIDELINES (8) HARS DATASET √
RETROVIRAL DRUGS
RIMEPORIDE DUCHENNE MUSCULAR DYSTROPHY NHS ENGLAND NEUROMUSCULAR DISORDERS NOT ROUTINELY COMMISSIONED AS PER IFR APPROVAL AS PER IFR APPROVAL AS PER IFR APPROVAL √
PULMONARY ARTERIAL HYPERTENSION NHS ENGLAND CLINICAL
RIOCIGUAT NHS ENGLAND DRUGS/PULMANORY ARTERIAL NHS ENGLAND POLICY NHS ENGLAND POLICY NHS ENGLAND POLICY √
(CTEPH) COMMISSIONING POLICY: A11/P/c
HYPERTENSION
RIOCIGUAT PULMONARY ARTERIAL HYPERTENSION NHS ENGLAND DRUGS/PULMANORY ARTERIAL NHS ENGLAND POLICY NHS ENGLAND POLICY NHS ENGLAND POLICY √
HYPERTENSION
RITONAVIR NHS ENGLAND AIDS/HIV ANTIRETROVIRALS AGREED REGIONALGUIDELINES BHIVA GUIDELINES (8) BHIVA GUIDELINES (8) HARS DATASET √
RETROVIRAL DRUGS
STEROID SENSITIVE NEPHROTIC NHS ENGLAND CLINICAL
RITUXIMAB NHS ENGLAND CYTOKINE MODULATORS NHS ENGLAND POLICY NHS ENGLAND POLICY NHS ENGLAND POLICY √
SYNDROME COMMISSIONING POLICY: E03/P/b
STEROID RESISTANT NEPHROTIC NHS ENGLAND CLINICAL
SYNDROME COMMISSIONING POLICY: E03/P/c
RITUXIMAB PRIMARY SJOGREN'S SYNDROME (PSS) NHS ENGLAND CYTOKINE MODULATORS AS PER IFR APPROVAL AS PER IFR APPROVAL AS PER IFR APPROVAL √
CHRONIC INFLAMMATORY NOT ROUTINELY COMMISSIONED
RITUXIMAB NHS ENGLAND CYTOKINE MODULATORS AS PER IFR APPROVAL AS PER IFR APPROVAL AS PER IFR APPROVAL √
DEMYELINATING POLYNEUROPATHY NHS ENGLAND POLICY 170026/P
RITUXIMAB JUVENILE ARTHRITIS-PAEDIATRIC NHS ENGLAND CYTOKINE MODULATORS NHS ENGLAND POLICY NHS ENGLAND POLICY NHS ENGLAND POLICY √ √
RITUXIMAB ACQUIRED HAEMOPHILIA NHS ENGLAND CYTOKINE MODULATORS NHS ENGLAND POLICY NHS ENGLAND POLICY NHS ENGLAND POLICY √
TA308 NICE/ NHS ENGLAND NICE/ NHS ENGLAND
RITUXIMAB ANCA-POSITIVE VASCULITIS NHS ENGLAND CYTOKINE MODULATORS NICE/ NHS ENGLAND POLICY √ √
NHS ENGLAND POLICY: A13/P/a POLICY POLICY
ANTI-NMDAR AUTOIMMUNE NHS ENGLAND CLINICAL
RITUXIMAB NHS ENGLAND CYTOKINE MODULATORS NHS ENGLAND POLICY NHS ENGLAND POLICY NHS ENGLAND POLICY √ √
ENCEPHALITIS COMMISSIONING POLICY:16036/P
CONNECTIVE TISSUE DISEASE - NOT ROUTINELY COMMISSIONED
INTERSTITIAL LUNG DISEASE NHS ENGLAND POLICY 170015/P
CYTOPENIA COMPLICATING PRIMARY NHS ENGLAND CLINICAL
IMMUNODEFICIENCY COMMISSIONING POLICY:16044/P
CHRONIC GRAFT VERSUS HOST NHS ENGLAND CLINICAL
DISEASE COMMISSIONING POLICY:16069/P
RITUXIMAB SLE NHS ENGLAND CYTOKINE MODULATORS NHS ENGLAND POLICY NHS ENGLAND POLICY NHS ENGLAND POLICY √ √
COMMISSIONING POLICY: A13/PS/a
RITUXIMAB MEMBRANOUS NEPHROPATHY NHS ENGLAND CYTOKINE MODULATORS AS PER IFR APPROVAL AS PER IFR APPROVAL AS PER IFR APPROVAL √
DERMATOMYOSITIS AND POLYMYOSITIS NHS ENGLAND CLINICAL
RITUXIMAB NHS ENGLAND CYTOKINE MODULATORS NHS ENGLAND POLICY NHS ENGLAND POLICY NHS ENGLAND POLICY √ √
(ADULTS) COMMISSIONING POLICY:16036/P
RITUXIMAB NEUROMYELITIS OPTICA NHS ENGLAND CYTOKINE MODULATORS AS PER SPECIFICATION AS PER SPECIFICATION AS PER SPECIFICATION AS PER SPECIFICATION √
SUITABLE FOR
SUITABLE FOR
SHARED CARE
CENTRE ONLY BETWEEN
PRIOR WITH PRIMARY
APPROVAL CARE (IF
REQUIRED LOCAL
PRESCRIBING
network) NETWORK
COMMITTEE)
MODEL
ABO-INCOMPATIBLE KIDNEY
RITUXIMAB NHS ENGLAND CYTOKINE MODULATORS AS PER SPECIFICATION AS PER SPECIFICATION AS PER SPECIFICATION AS PER SPECIFICATION √
TRANSPLANTS
PEMPHIGUS VULGARIS AND NHS ENGLAND CLINICAL
PEMPHIGOID DISEASE COMMISSIONING POLICY:16035/P
RITUXIMAB IMMUNOGLOBIN G4 RELATED DISEASE NHS ENGLAND CYTOKINE MODULATORS NHS ENGLAND POLICY NHS ENGLAND POLICY NHS ENGLAND POLICY √
COMMISSIONING POLICY:16057/P
RITUXIMAB MYASTHENIA GRAVIS NHS ENGLAND CYTOKINE MODULATORS COMMISSIONING POLICY STATEMENT NHS ENGLAND POLICY NHS ENGLAND POLICY NHS ENGLAND POLICY √ √
170084P
FOCAL SEGMENTAL NOT ROUTINELY COMMISSIONED

GLOMERULOSCLEROSIS NHS ENGLAND POLICY STATEMENT 1818
TA65, TA137, TA174, TA193, TA65, TA137, TA174, TA193,

TA65, TA137, TA174, TA193, TA226, TA243
RITUXIMAB IV CANCER NHS ENGLAND CYTOKINE MODULATORS TA226, TA243 TA226, TA243 SACT √
NHS ENGLAND CDF LETTER
NHS ENGLAND CDF LETTER NHS ENGLAND CDF LETTER
AS PER CIRCULAR IE ONLY

RITUXIMAB SUBCUTANEOUS
CANCER NHS ENGLAND CYTOKINE MODULATORS COMMISSIONED FOR FOLLICULAR AS PER CIRCULAR AS PER CIRCULAR SACT √
FORMULATION
LYMPHOMA MAINTENANCE TREATMENT
RIVIPANSEL SODIUM HEPATIC VENO-OCCLUSIVE DISEASE NHS ENGLAND NOVEL - NO GROUP NAME AGREED NOT ROUTINELY COMMISSIONED AS PER IFR APPROVAL AS PER IFR APPROVAL AS PER IFR APPROVAL √
RIVIPANSEL SODIUM SICKLE CELL DISEASE NHS ENGLAND NOVEL - NO GROUP NAME AGREED NOT ROUTINELY COMMISSIONED AS PER IFR APPROVAL AS PER IFR APPROVAL AS PER IFR APPROVAL √
ROMIPLOSTIM ITP IN CHILDREN NHS ENGLAND PLATELET DISORDER DRUGS AS PER ADULT TA 221 NICE NICE NICE AUDIT √ √
ROPEGINTERFERON ALFA-2b HEPATITIS C NHS ENGLAND NOT ROUTINELY COMMISSIONED AS PER IFR APPROVAL AS PER IFR APPROVAL AS PER IFR APPROVAL √

ROXADUSTAT DIALYSIS-INDUCED ANAEMIA NHS ENGLAND NOT ROUTINELY COMMISSIONED AS PER IFR APPROVAL AS PER IFR APPROVAL AS PER IFR APPROVAL √
HAEMOLYTIC, AND RENAL ANAEMIAS
RURIOCTOCOG ALFA PEGOL HAEMOPHILIA A NHS ENGLAND BLOOD-RELATED PRODUCTS NOT ROUTINELY COMMISSIONED AS PER IFR APPROVAL AS PER IFR APPROVAL AS PER IFR APPROVAL √
RUZASVIR HEPATITIS C NHS ENGLAND NOT ROUTINELY COMMISSIONED AS PER IFR APPROVAL AS PER IFR APPROVAL AS PER IFR APPROVAL √
RUXOLITINIB CANCER NHS ENGLAND PROTEIN KINASE INHIBITORS TA 386 NICE NICE SACT √
CONGENITAL SUCRASE ISOMALTASE DRUGS USED IN METABOLIC
SACROSIDASE NHS ENGLAND NOT ROUTINELY COMMISSIONED AS PER IFR APPROVAL AS PER IFR APPROVAL AS PER IFR APPROVAL √
DEFICIENCY DISORDERS
ADULTS AND CHILDREN WITH DRUGS USED IN METABOLIC
SAPROPTERIN NHS ENGLAND (NHS ENGLAND CLINICAL AS PER IFR APPROVAL AS PER IFR APPROVAL AS PER IFR APPROVAL √
PHENYLKETONURIA DISORDERS
COMMISSIONING POLICY: 170103P)
SAPROPTERIN MATERNAL PHENYLKETONURIA NHS ENGLAND NHS ENGLAND POLICY NHS ENGLAND POLICY HIGHLY SPECIALISED DATABASE √
DISORDERS COMMISSIONING POLICY: E12/P/a
SAQUINAVIR NHS ENGLAND AIDS/HIV ANTIRETROVIRALS AGREED REGIONALGUIDELINES BHIVA GUIDELINES (8) BHIVA GUIDELINES (8) HARS DATASET √
RETROVIRAL DRUGS
SATRALIZUMAB NEUROMYELITIS OPTICA NHS ENGLAND CYTOKINE MODULATORS NOT ROUTINELY COMMISSIONED AS PER IFR APPROVAL AS PER IFR APPROVAL AS PER IFR APPROVAL √
DRUGS USED IN METABOLIC NOT ROUTINELY COMMISSIONED
SEBELIPASE ALFA LYSOSOMAL ACID LIPASE DEFICIENCY NHS ENGLAND AS PER IFR APPROVAL AS PER IFR APPROVAL AS PER IFR APPROVAL √
DISORDERS NICE HST IN PROGRESS
SELEXIPAG PULMONARY ARTERIAL HYPERTENSION NHS ENGLAND DRUGS/PULMANORY ARTERIAL NHS ENGLAND POLICY NHS ENGLAND POLICY NHS ENGLAND POLICY √
HYPERTENSION
DRUGS AFFECTING BONE

SETRUSUMAB OSTEOGENESIS IMPERFECTA NHS ENGLAND NOT ROUTINELY COMMISSIONED AS PER IFR APPROVAL AS PER IFR APPROVAL AS PER IFR APPROVAL √
METABOLISM
SEVELAMER ADULT RENAL DIALYSIS ONLY NHS ENGLAND PHOSPHATE BINDING AGENTS AGREED TRUST GUIDELINES TRUST GUIDELINES TRUST GUIDELINES √
SIPONIMOD MULTIPLE SCLEROSIS NHS ENGLAND IMMUNOMODULATING DRUGS NOT ROUTINELY COMMISSIONED AS PER IFR APPROVAL AS PER IFR APPROVAL AS PER IFR APPROVAL √
TA481, TA482
TRANSPLANT IMMUNOSUPPRESSION DRUGS AFFECTING THE IMMUNE PRODUCT WITH LOWEST
SIROLIMUS (RAPAMUNE) NHS ENGLAND NEW PATIENTS ONLY UNTIL FORMAL NICE NICE √* √*
ONLY RESPONSE PROCUREMENT COST TO BE USED
REPATRIATION AGREED
NARCOLEPSY - PEADIATRIC SERVICES NHS ENGLAND CLINICAL
SODIUM OXYBATE NHS ENGLAND HYPNOTICS & ANXIOLYTICS NHS ENGLAND POLICY NHS ENGLAND POLICY NHS ENGLAND POLICY √ √
ONLY COMMISSIONING POLICY: 16065/P
SODIUM PHENYLBUTYRATE UREA CYCLE DISORDERS NHS ENGLAND NHS ENGLAND SERVICE SPECIFICATION HIGHLY SPECIALISED DATABASE √
SOFOSBUVIR/LEDIPASVIR +/- VIRAL HEPATITIS (B&C) &
RIBAVIRIN RESPIRATORY SYNCYTIAL VIRUS
SOFOSBUVIR/PEGINTERFERON+ VIRAL HEPATITIS (B&C) &
RIBAVIRIN RESPIRATORY SYNCYTIAL VIRUS
SOFOSBUVIR/VELPATASVIR HEPATITIS C NHS ENGLAND TA 430 AS PER RUN RATE CARD AS PER RUN RATE CARD HEPATITIS C MDS √ √
SORAFENIB CANCER NHS ENGLAND PROTEIN KINASE INHIBITORS TA 474 & TA 535 NICE NICE SACT √ √
STAVUDINE NHS ENGLAND AIDS/HIV ANTIRETROVIRALS AGREED REGIONALGUIDELINES BHIVA GUIDELINES (8) BHIVA GUIDELINES (8) HARS DATASET √
RETROVIRAL DRUGS
CLINICAL GUIDELINES FOR
IMMUNOGLOBULIN USE, SECOND
QUALITY DASHBOARD
SUBCUTANEOUS HUMAN NORMAL INTRAVENOUS/SUBCUTANEOUS EDITION UPDATE (JULY 2011)
MULTIPLE INDICATIONS NHS ENGLAND NATIONAL GUIDELINES NATIONAL GUIDELINES NATIONAL IMMUNOGLOBULIN DATA √
IMMUNOGLOBULINS HUMAN NORMAL IMMUNOGLOBULINS IMMUNOGLOBULIN GUIDELINES
BASE
PUBLISHED 2019 ON MDSAS WEBSITE
SUCROFERRIC OXYHDROXIDE ADULT RENAL DIALYSIS ONLY NHS ENGLAND PHOSPHATE BINDING AGENTS AGREED TRUST GUIDELINES TRUST GUIDELINES TRUST GUIDELINES √
SUNITINIB CANCER NHS ENGLAND PROTEIN KINASE INHIBITORS TA169, TA179, TA449 NICE NICE SACT √ (Only TA449) √
SUTIMLIMAB PRIMARY COLD AGGLUTININ DISEASE NHS ENGLAND BLOOD-RELATED PRODUCTS NOT ROUTINELY COMMISSIONED AS PER IFR APPROVAL AS PER IFR APPROVAL AS PER IFR APPROVAL √
TABALUMAB SLE NHS ENGLAND CYTOKINE MODULATORS NOT ROUTINELY COMMISSIONED AS PER IFR APPROVAL AS PER IFR APPROVAL AS PER IFR APPROVAL √
TAFAMIDIS AMYLOIDOSIS NHS ENGLAND NEURODEGENERATIVE CONDITIONS NOT ROUTINELY COMMISSIONED AS PER IFR APPROVAL AS PER IFR APPROVAL AS PER IFR APPROVAL √

TALIGLUCERASE ALFA GAUCHER'S DISEASE NHS ENGLAND NHS ENGLAND SERVICE SPECIFICATION HIGHLY SPECIALISED DATABASE √
TARIBAVIRIN HEPATITIS C NHS ENGLAND NOT ROUTINELY COMMISSIONED AS PER IFR APPROVAL AS PER IFR APPROVAL AS PER IFR APPROVAL √
TEDUGLUTIDE SHORT BOWEL SYNDROME NHS ENGLAND CYTOKINE MODULATORS NOT ROUTINELY COMMISSIONED AS PER IFR APPROVAL AS PER IFR APPROVAL AS PER IFR APPROVAL √
VIRAL HEPATITIS (B&C) & NOT ROUTINELY COMMISSIONED
TELBIVUDINE HEPATITIS B NHS ENGLAND AS PER IFR APPROVAL AS PER IFR APPROVAL AS PER IFR APPROVAL √
RESPIRATORY SYNCYTIAL VIRUS (TA154)
TEMSIROLIMUS CANCER NHS ENGLAND PROTEIN KINASE INHIBITORS IFR IFR SACT √
(TA178)
RETROVIRAL DRUGS TA173 (FOR HEPATITIS B)/AGREED BHIVA GUIDELINES (8) BHIVA GUIDELINES (8)
TENOFOVIR NHS ENGLAND AIDS/HIV ANTIRETROVIRALS HARS DATASET √
HEPATITIS B +/- OTHER ANTI- REGIONAL GUIDELINES FOR HIV NICE NICE
RETROVIRAL DRUGS
TENOFOVIR ALAFENAMIDE HEPATITIS B NHS ENGLAND AIDS/HIV ANTIRETROVIRALS NOT ROUTINELY COMMISSIONED AS PER IFR APPROVAL AS PER IFR APPROVAL AS PER IFR APPROVAL √
HIV IN COMBINATION WITH OTHER ANTI- NHS ENGLAND CLINICAL
TENOFOVIR ALAFENAMIDE NHS ENGLAND AIDS/HIV ANTIRETROVIRALS NHS ENGLAND POLICY NHS ENGLAND POLICY HARS DATASET √
RETROVIRAL DRUGS COMMISSIONING POLICY: 16043/P
TENOFOVIR ALAFENAMIDE +
HIV IN COMBINATION WITH OTHER ANTI- NHS ENGLAND CLINICAL
COBICISTAT + ELVITEGRAVIR + NHS ENGLAND AIDS/HIV ANTIRETROVIRALS NHS ENGLAND POLICY NHS ENGLAND POLICY HARS DATASET √
RETROVIRAL DRUGS COMMISSIONING POLICY: 16043/P
EMTRICITABINE
SUITABLE FOR
SUITABLE FOR
SHARED CARE
CENTRE ONLY BETWEEN
PRIOR WITH PRIMARY
APPROVAL CARE (IF
REQUIRED LOCAL
PRESCRIBING
network) NETWORK
COMMITTEE)
MODEL
TENOFOVIR DISOPROXIL + NHS ENGLAND CLINICAL

COBICISTAT + ELVITEGRAVIR + NHS ENGLAND AIDS/HIV ANTIRETROVIRALS COMMISSIONING POLICY: NHS ENGLAND POLICY NHS ENGLAND POLICY HARS DATASET √
RETROVIRAL DRUGS
EMTRICITABINE F03/P/b/AGREED REGIONAL GUIDELINES
TENOFOVIR + EMTRICITABINE + HIV IN COMBINATION WITH OTHER ANTI-

EFAVIRENZ RETROVIRAL DRUGS
TENOFOVIR + EMTRICITABINE + HIV IN COMBINATION WITH OTHER ANTI-
RILPIVIRINE RETROVIRAL DRUGS
TEPRASIRAN NHS ENGLAND RENAL TRANSPLANTATION NOT ROUTINELY COMMISSIONED AS PER IFR APPROVAL AS PER IFR APPROVAL AS PER IFR APPROVAL √
FUNCTION
TEPROTUMUMAB GRAVES ORBITOPATHY NHS ENGLAND IMMUNOMODULATING DRUGS NOT ROUTINELY COMMISSIONED AS PER IFR APPROVAL AS PER IFR APPROVAL AS PER IFR APPROVAL √
TA303
TERIFLUNOMIDE MULTIPLE SCLEROSIS NHS ENGLAND IMMUNOMODULATING DRUGS NICE NICE NICE AUDIT √ √****
DRUGS AFFECTING BONE NOT ROUTINELY COMMISSIONED
TERIPARATIDE OSTEOGENESIS IMPERFECTA NHS ENGLAND AS PER IFR APPROVAL AS PER IFR APPROVAL AS PER IFR APPROVAL √
METABOLISM NHS ENGLAND POLICY: 16002/P
TERIPARATIDE MALE AND JUVENILE OSTEOPOROSIS NHS ENGLAND COMMISSIONING POLICY STATEMENT NHS ENGLAND POLICY NHS ENGLAND POLICY NHS ENGLAND POLICY √
METABOLISM
170064P
TETRAHYDROBIOPTERIN PHENYLKETONURIA NHS ENGLAND NHS ENGLAND SERVICE SPECIFICATION HIGHLY SPECIALISED DATABASE √
NHS ENGLAND URGENT POLICY
TEZACAFTOR WITH IVACAFTOR CYSTIC FIBROSIS NHS ENGLAND MUCOLYTICS NHS ENGLAND POLICY NHS ENGLAND POLICY AS PER POLICY √
STATEMENT 190137P
TEZEPELUMAB ASTHMA NHS ENGLAND ALLERGEN IMMUNOTHERAPY NOT ROUTINELY COMMISSIONED AS PER IFR APPROVAL AS PER IFR APPROVAL AS PER IFR APPROVAL √
THALIDOMIDE CANCER NHS ENGLAND IMMUNOMODULATING DRUGS TA228 NICE NICE SACT √
THROMBOMODULIN,
PSEUDOANEURYSM NHS ENGLAND BLOOD-RELATED PRODUCTS IPG060 IPG060 NICE √
RECOMBINANT HUMAN

TIPRANAVIR NHS ENGLAND AIDS/HIV ANTIRETROVIRALS AGREED REGIONALGUIDELINES BHIVA GUIDELINES (8) BHIVA GUIDELINES (8) HARS DATASET √
RETROVIRAL DRUGS
TOBRAMYCIN CYSTIC FIBROSIS NHS ENGLAND ANTIBACTERIAL DRUGS COMMISSIONING POLICY: A01/P/b √* √*
TA276
TOCILIZUMAB ADULT ONSET STILLS DISEASE NHS ENGLAND CYTOKINE MODULATORS NHS ENGLAND POLICY NHS ENGLAND POLICY NHS ENGLAND POLICY √ √

TOCILIZUMAB JUVENILE ARTHRITIS-PAEDIATRIC NHS ENGLAND CYTOKINE MODULATORS NHS ENGLAND POLICY NHS ENGLAND POLICY NHS ENGLAND POLICY √ √

TOCILIZUMAB TAKAYASU ARTERITIS NHS ENGLAND CYTOKINE MODULATORS NHS ENGLAND POLICY NHS ENGLAND POLICY NHS ENGLAND POLICY √
COMMISSIONING POLICY 16056/P
TOCILIZUMAB GIANT CELL ARTERITIS NHS ENGLAND CYTOKINE MODULATORS TA 518 NICE NICE NICE AUDIT √ √
TOCILIZUMAB CYTOKINE RELEASE SYNDROME NHS ENGLAND CYTOKINE MODULATORS AS PER BLUETEQ FORM AS PER BLUETEQ FORM AS PER BLUETEQ FORM BLUETEQ AUDIT √ √
POSTERIOR PITUITARY HORMONES NHS ENGLAND CLINICAL
TOLVAPTAN HYPONATRAEMIA IN CANCER NHS ENGLAND NHS ENGLAND POLICY NHS ENGLAND POLICY NHS ENGLAND POLICY √
AND ANTAGONISTS COMMISSIONING POLICY 16051/P
TRALOKINUMAB ASTHMA NHS ENGLAND ALLERGEN IMMUNOTHERAPY NOT ROUTINELY COMMISSIONED AS PER IFR APPROVAL AS PER IFR APPROVAL AS PER IFR APPROVAL √
TRENONACOG ALPHA HAEMOPHILIA B NHS ENGLAND BLOOD-RELATED PRODUCTS NOT ROUTINELY COMMISSIONED AS PER IFR APPROVAL AS PER IFR APPROVAL AS PER IFR APPROVAL √
TRIENTENE WILSONS DISEASE NHS ENGLAND NHS ENGLAND POLICY NHS ENGLAND POLICY NHS ENGLAND POLICY √ √
DISORDERS COMMISSIONING POLICY 170094P
TRIHEPTANOIN PYRUVATE CARBOXYLASE DEFICIENCY NHS ENGLAND NOT ROUTINELY COMMISSIONED AS PER IFR APPROVAL AS PER IFR APPROVAL AS PER IFR APPROVAL √
DISORDERS
UPRIFOSBUVIR HEPATITIS C NHS ENGLAND NOT ROUTINELY COMMISSIONED AS PER IFR APPROVAL AS PER IFR APPROVAL AS PER IFR APPROVAL √
USTEKINUMAB PLAQUE PSORIASIS IN CHILDREN NHS ENGLAND CYTOKINE MODULATORS TA455 NICE NICE NICE AUDIT √ √

VADADUSTAT DIALYSIS-INDUCED ANAEMIA NHS ENGLAND NOT ROUTINELY COMMISSIONED AS PER IFR APPROVAL AS PER IFR APPROVAL AS PER IFR APPROVAL √
HAEMOLYTIC, AND RENAL ANAEMIAS

VALGANCICLOVIR CYTOMEGALOVIRUS NHS ENGLAND CYTOMEGALOVIRUS INFECTION AGREED TRUST GUIDELINES TRUST GUIDELINES TRUST GUIDELINES PROPORTION GIVEN FOR SPC √
VANDETANIB THYROID CANCER NHS ENGLAND PROTEIN KINASE INHIBITORS IFR IFR SACT √
(TA550)
VATIQUINONE FRIEDREICHS ATAXIA NHS ENGLAND NEURODEGENERATIVE CONDITIONS NOT ROUTINELY COMMISSIONED AS PER IFR APPROVAL AS PER IFR APPROVAL AS PER IFR APPROVAL √

VELAGLUCERASE ALFA GAUCHER'S DISEASE NHS ENGLAND NHS ENGLAND SERVICE SPECIFICATION HIGHLY SPECIALISED DATABASE √

VELCALCETIDE HYPERPARATHYROIDISM NHS ENGLAND NOT ROUTINELY COMMISSIONED AS PER IFR APPROVAL AS PER IFR APPROVAL AS PER IFR APPROVAL √
METABOLISM
DRUGS USED TO TREAT ALPHA
VELMANASE ALFA ALPHA MANNOSIDASE DEFICIENCY NHS ENGLAND NOT ROUTINELY COMMISSIONED AS PER IFR APPROVAL AS PER IFR APPROVAL AS PER IFR APPROVAL √
MANNOSIDOSIS
VEMURAFENIB MELANOMA NHS ENGLAND PROTEIN KINASE INHIBITORS TA269 NICE NICE NICE AUDIT √
VESTRONIDASE ALFA MUCOPOLYSACCHARIDOSIS VII NHS ENGLAND NOT ROUTINELY COMMISSIONED AS PER IFR APPROVAL AS PER IFR APPROVAL AS PER IFR APPROVAL √
DRUGS
FAMILIAL CHYLOMICRONEMIA
VOLANESORSEN NHS ENGLAND LIPID-REGULATING DRUGS NOT ROUTINELY COMMISSIONED AS PER IFR APPROVAL AS PER IFR APPROVAL AS PER IFR APPROVAL √
SYNDROME
VONICOG ALFA VON WILLEBRAND DEFICIENCY NHS ENGLAND BLOOD-RELATED PRODUCTS NOT ROUTINELY COMMISSIONED AS PER IFR APPROVAL AS PER IFR APPROVAL AS PER IFR APPROVAL √
VON WILLEBRAND FACTOR,
VON WILLEBRAND DEFICIENCY NHS ENGLAND BLOOD-RELATED PRODUCTS NOT ROUTINELY COMMISSIONED AS PER IFR APPROVAL AS PER IFR APPROVAL AS PER IFR APPROVAL √
RECOMBINANT
RETINAL DISORDERS/INTRAOCULAR
VORETIGENE NEPARVOVEC INHERITED RETINAL DYSTROPHIES NHS ENGLAND HST11 NICE NICE NICE AUDIT √ √
LENS REPLACEMENT SURGERY

VORICONAZOLE FUNGAL INFECTION NHS ENGLAND ANTIFUNGALS AGREED TRUST GUIDELINES TRUST GUIDELINES TRUST GUIDELINES PROPORTION GIVEN FOR SPC √
VORICONAZOLE CHRONIC PULMONARY ASPERGILLOSIS NHS ENGLAND ANTIFUNGALS HIGHLY SPECIALISED CRITERIA ONLY √
VOXELOTOR SICKLE CELL DISEASE NHS ENGLAND NOVEL - NO GROUP NAME AGREED NOT ROUTINELY COMMISSIONED AS PER IFR APPROVAL AS PER IFR APPROVAL AS PER IFR APPROVAL √
VX-210 SPINAL CORD INJURY NHS ENGLAND NOVEL - NO GROUP NAME AGREED NOT ROUTINELY COMMISSIONED AS PER IFR APPROVAL AS PER IFR APPROVAL AS PER IFR APPROVAL √
NOT ROUTINELY COMMISSIONED - NHS
ZICONOTIDE INTRATHECAL ANALGESIA NHS ENGLAND NON-OPIOID ANALGESICS AS PER IFR APPROVAL AS PER IFR APPROVAL AS PER IFR APPROVAL √
ENGLAND POLICY 16011/P
ZIDOVUDINE NHS ENGLAND AIDS/HIV ANTIRETROVIRALS AGREED REGIONALGUIDELINES BHIVA GUIDELINES (8) BHIVA GUIDELINES (8) HARS DATASET √
RETROVIRAL DRUGS
ZIDOVUDINE + LAMIVUDINE NHS ENGLAND AIDS/HIV ANTIRETROVIRALS AGREED REGIONALGUIDELINES BHIVA GUIDELINES (8) BHIVA GUIDELINES (8) HARS DATASET √
RETROVIRAL DRUGS
ZIDOVUDINE + LAMIVUDINE + HIV IN COMBINATION WITH OTHER ANTI-
ABACAVIR RETROVIRAL DRUGS
OTHER DRUGS NOT LISTED
UNDER PBR EXCLUSIONS
LAMBERT EATON MYASTHENIC
3,4 DIAMINOPYRIDINE NHS ENGLAND AGREED TRUST GUIDELINES TRUST GUIDELINES TRUST GUIDELINES √
SYNDROME
SUITABLE FOR
SUITABLE FOR
SHARED CARE
CENTRE ONLY BETWEEN
PRIOR WITH PRIMARY
APPROVAL CARE (IF
REQUIRED LOCAL
PRESCRIBING
network) NETWORK
COMMITTEE)
MODEL
TA563 NICE NICE
ABEMACICLIB CANCER CDF CANCER EXCLUSION SACT √ √
CDF TA579 CDF CDF
ALBUMIN BOUND PACLITAXEL CANCER NHS ENGLAND CANCER EXCLUSION TA 476 NICE NICE SACT √ √
ALECTINIB CANCER NHS ENGLAND CANCER EXCLUSION TA 536 NICE NICE SACT √ √
TA 526
ARSENIC TRIOXIDE CANCER NHS ENGLAND CANCER EXCLUSION NICE NICE SACT √ √
NHS ENGLAND POLICY STATEMENT
170072P
NHS ENGLAND/ TA520, TA525, TA584 NICE NICE

ATEZOLIZUMAB CANCER CANCER EXCLUSION SACT √ √
CDF CDF (TA 492) CDF CDF
AUTOLOGOUS CHONDROCYTE
ARTICULAR CARTILAGE DEFECT NHS ENGLAND TA 477 & TA 508 NICE NICE NICE AUDIT √ √
IMPLANTATION
TA 517 NICE NICE

AVELUMAB CANCER NHS ENGLAND CANCER EXCLUSION SACT √ √
CDF CDF CDF
AXICABTAGENE CILOLEUCEL CANCER CDF ATMP TA 559 CDF CDF SACT √ √

TRANSPLANT IMMUNOSUPPRESSION NEW PATIENTS ONLY UNTIL FORMAL
AZATHIOPRINE NHS ENGLAND TRUST GUIDELINES TRUST GUIDELINES √* √*
ONLY REPATRIATION AGREED
TA216
NICE NICE
NHS ENGLAND/ CDF POLICY √ (Not for all
BENDAMUSTINE CANCER CANCER EXCLUSION CDF CDF SACT √
CDF NHS ENGLAND POLICY (WITH policies)
NHS ENGLAND POLICY NHS ENGLAND POLICY
RITUXIMAB) 170055P, 17088P & 170054P
BINIMETINIB CANCER NHS ENGLAND CANCER EXCLUSION TA562 NICE NICE SACT √ √
BLINATUMOMAB CANCER NHS ENGLAND CANCER EXCLUSION TA450, TA589 NICE NICE SACT √ √
TA446 (replaced by TA524), TA478, TA524,
BRENTUXIMAB CANCER NHS ENGLAND CANCER EXCLUSION NICE NICE SACT √ √
TA577
BRIGATINIB CANCER NHS ENGLAND CANCER EXCLUSION TA571 NICE NICE SACT √ √
CABAZITAXEL CANCER NHS ENGLAND CANCER EXCLUSION TA 391 NICE NICE SACT √ √
CABOZANTINIB CANCER NHS ENGLAND/CDF CANCER EXCLUSION TA 463, TA516 & TA 542 NICE NICE SACT √ √
CARFILZOMIB CANCER NHS ENGLAND CANCER EXCLUSION TA 457 NICE NICE SACT √ √
CEMIPLIMAB CANCER CDF CANCER EXCLUSION TA 592 (CDF) CDF CDF SACT √ √
CERITINIB CANCER NHS ENGLAND CANCER EXCLUSION TA 395, TA 500 NICE NICE SACT √ √
NHS ENGLAND/ TRUST GUIDELINES/ NICE/ TRUST GUIDELINES/ NICE/
CHEMOTHERAPY CANCER - (NOT SPECIFICALLY LISTED) CANCER EXCLUSION TRUST GUIDELINES/ NICE/ CDF POLICY SACT √
CDF CDF POLICY CDF POLICY
TRANSPLANT IMMUNOSUPPRESSION NEW PATIENTS ONLY UNTIL FORMAL PRODUCT WITH LOWEST
CICLOSPORIN NHS ENGLAND TRUST GUIDELINES TRUST GUIDELINES √* √*
ONLY REPATRIATION AGREED PROCUREMENT COST TO BE USED
CDF POLICY
CLOFARABINE CANCER CDF CANCER EXCLUSION NOT ROUTINELY COMMISSIONED - NHS CDF CDF SACT √
ENGLAND POLICY 170080P
DRUGS FOR MINERAL BONE
COLESTILAN ADULT RENAL DIALYSIS ONLY NHS ENGLAND TRUST GUIDELINES TRUST GUIDELINES TRUST GUIDELINES √
DISORDERS
DACOMITINIB CANCER NHS ENGLAND CANCER EXCLUSION TA595 NICE NICE SACT √ √
DARATUMUMAB CANCER CDF CANCER EXCLUSION CDF (TA 510, TA 573) CDF CDF SACT √ √
DINUTUXIMAB CANCER NHS ENGLAND CANCER EXCLUSION TA 538 NICE NICE SACT √ √
DOCETAXEL CANCER NHS ENGLAND CANCER EXCLUSION COMMISSIONING POLICY STATEMENT NHS ENGLAND POLICY NHS ENGLAND POLICY SACT √
B15/PS/a
DURVALUMAB CANCER CDF CANCER EXCLUSION CDF TA578 CDF CDF SACT √ √
ENCORAFENIB CANCER NHS ENGLAND CANCER EXCLUSION TA562 NICE NICE SACT √ √
ERIBULIN CANCER NHS ENGLAND CANCER EXCLUSION NICE TA 423 NICE NICE SACT √ √
FACTOR X (COAGADEX) HEREDITARY FACTOR X DEFICIENCY NHS ENGLAND BLOOD-RELATED PRODUCTS NOT ROUTINELY COMMISSIONED AS PER IFR APPROVAL AS PER IFR APPROVAL AS PER IFR APPROVAL √
GEMCITABINE (WITH
CANCER NHS ENGLAND CANCER EXCLUSION NHS ENGLAND POLICY 170101P NHS ENGLAND POLICY NHS ENGLAND POLICY SACT √ √
CAPECITABINE)
GEMTUZUMAB OZOGAMICIN CANCER NHS ENGLAND CANCER EXCLUSION TA 545 NICE NICE SACT √ √
TA429, TA502 NICE NICE
IBRUTINIB CANCER NHS ENGLAND/CDF PROTEIN KINASE INHIBITORS SACT √ √
CDF (TA491) CDF CDF
IDELALISIB CANCER NHS ENGLAND PROTEIN KINASE INHIBITORS NICE TA 359 NICE NICE SACT √
INOTUZUMAB OZOGAMICIN CANCER NHS ENGLAND CANCER EXCLUSION TA 541 NICE NICE SACT √ √
NICE NICE
IPILIMUMAB CANCER NHS ENGLAND/CDF CANCER EXCLUSION TA268, TA319, TA400, CDF TA581 SACT √ √
CDF CDF
LENVATINIB CANCER NHS ENGLAND PROTEIN KINASE INHIBITORS TA498, TA 535 & TA 551 NICE NICE SACT √ √
LIPOSOMAL CYTARABINE-
CANCER NHS ENGLAND CANCER EXCLUSION TA 522 NICE NICE SACT √ √
DAUNORUBICIN
LUTETIUM (177Lu)
CANCER NHS ENGLAND CANCER EXCLUSION TA 539 NICE NICE SACT √ √
OXODOTREOTIDE
MESENCHYMAL STEM CELLS (E.G. ACUTE GVHD AND OTHER INDICATIONS
PROCHYMAL®) (BCSH)
MIDOSTAURIN CANCER NHS ENGLAND CANCER EXCLUSION TA 523 NICE NICE SACT √ √
TA481, TA482
TRANSPLANT IMMUNOSUPPRESSION PRODUCT WITH LOWEST
MYCOPHENOLATE MOFETIL NHS ENGLAND NEW PATIENTS ONLY UNTIL FORMAL NICE NICE √* √*
ONLY PROCUREMENT COST TO BE USED
REPATRIATION AGREED
TA481, TA482
MYCOPHENOLIC ACID NHS ENGLAND NEW PATIENTS ONLY UNTIL FORMAL NICE NICE √* √*
REPATRIATION AGREED
NELARABINE CANCER CDF CANCER EXCLUSION CDF POLICY CDF CDF SACT √
NERATINIB CANCER NHS ENGLAND CANCER EXCLUSION TA612 NICE NICE SACT √ √
NIRAPARIB CANCER CDF CANCER EXCLUSION CDF (TA 528) CDF CDF SACT √ √
TA 384, 400, 417, 462, 530
NICE NICE
NIVOLUMAB CANCER NHS ENGLAND/CDF CANCER EXCLUSION CDF (TA 483, TA 484, TA 490, TA 558, TA SACT √ √
CDF CDF
581)
SUITABLE FOR
SUITABLE FOR
SHARED CARE
CENTRE ONLY BETWEEN
PRIOR WITH PRIMARY
APPROVAL CARE (IF
REQUIRED LOCAL
PRESCRIBING
network) NETWORK
COMMITTEE)
MODEL
TA343 & 513 NICE NICE
OBINUTUZUMAB CANCER NHS ENGLAND/CDF CANCER EXCLUSION SACT √ √
CDF (TA472) CDF CDF
NICE NICE
OLAPARIB CANCER NHS ENGLAND/CDF CANCER EXCLUSION TA 381, CDF TA598, TA620 SACT √ √
CDF CDF
OSIMERTINIB CANCER CDF CANCER EXCLUSION CDF (TA 416) CDF CDF SACT √ √
NICE NICE
PALBOCICLIB CANCER NHS ENGLAND/CDF CANCER EXCLUSION TA 495 & TA 619 (CDF) SACT √ √
CDF CDF
PANITUMUMAB CANCER NHS ENGLAND CANCER EXCLUSION TA439 NICE NICE SACT √ √
PANOBINOSTAT CANCER NHS ENGLAND CANCER EXCLUSION TA 380 NICE NICE SACT √
PEGASPARGASE CANCER NHS ENGLAND CANCER EXCLUSION TA 408 NICE NICE SACT √
PEGYLATED LIPOSOMAL NHS ENGLAND/ TA91 NICE NICE

CANCER CANCER EXCLUSION SACT √
DOXORUBICIN CDF CDF POLICY CDF CDF
TA135, TA181, TA190, TA 402
PEMETREXED CANCER NHS ENGLAND CANCER EXCLUSION NICE NICE SACT √
PEPTIDE RECEPTOR
CANCER CDF NOT ROUTINELY COMMISSIONED AS PER IFR APPROVAL AS PER IFR APPROVAL AS PER IFR APPROVAL √
RADIONUCLEOTIDE THERAPY
PERTUZUMAB CANCER NHS ENGLAND CANCER EXCLUSION NICE TA 424, TA 509 and TA 569 NICE NICE SACT √ √
PIXANTRONE CANCER NHS ENGLAND CANCER EXCLUSION TA306 NICE NICE SACT √
ENDOCRINOLOGY; NON-MALIGNANT
PROTEIN KINASE INHIBITORS NHS ENGLAND NOT ROUTINELY COMMISSIONED AS PER IFR APPROVAL AS PER IFR APPROVAL AS PER IFR APPROVAL √
CONDITIONS
RADIUM-223 DICHLORIDE CANCER NHS ENGLAND CANCER EXCLUSION NICE TA 376 replaced by TA 412 NICE NICE SACT √ √
NOT ROUTINELY COMMISSIONED -

RAMUCIRUMAB CANCER NHS ENGLAND CANCER EXCLUSION AS PER IFR APPROVAL AS PER IFR APPROVAL SACT √
TA 378
NICE NICE
RIBOCICLIB CANCER NHS ENGLAND/CDF CANCER EXCLUSION TA 496, CDF TA593 SACT √ √
CDF CDF
RUCAPARIB CANCER NHS ENGLAND/CDF CANCER EXCLUSION CDF TA611 CDF CDF SACT √ √
ADENOSINE DEAMINASE DEFICIENCY-
STRIMVELIS SEVERE COMBINED NHS ENGLAND ATMP HST7 NICE NICE NICE AUDIT √
IMMUNODEFICIENCY
TA481, TA482
TACROLIMUS NHS ENGLAND NEW PATIENTS ONLY UNTIL FORMAL NICE NICE √* √*
REPATRIATION AGREED
TALIMOGENE LAHERPAREPVEC CANCER NHS ENGLAND CANCER EXCLUSION TA 410 NICE NICE SACT √ √
TA23 & TA121 NICE NICE
TEMOZOLOMIDE CANCER NHS ENGLAND CANCER EXCLUSION SACT √ √
NHS ENGLAND POLICY 200203P NHS ENGLAND POLICY NHS ENGLAND POLICY
ENDOCRINOLOGY; NON-MALIGNANT
TEMOZOLOMIDE NHS ENGLAND CANCER EXCLUSION NOT ROUTINELY COMMISSIONED AS PER IFR APPROVAL AS PER IFR APPROVAL AS PER IFR APPROVAL √
CONDITIONS
NICE NICE
TISAGENLECLEUCEL CANCER CDF ATMP CDF (TA 554, TA 567) SACT √ √
CDF CDF
TIVOZANIB CANCER NHS ENGLAND CANCER EXCLUSION TA 512 NICE NICE SACT √ √
TRABECTEDIN CANCER NHS ENGLAND ANTINEOPLASTIC DRUGS TA185 NICE NICE SACT √
TRAMETINIB CANCER NHS ENGLAND CANCER EXCLUSION TA 396 & TA 544 NICE NICE SACT √ √
TRASTUZUMAB CANCER NHSE ENGLAND CANCER EXCLUSION TA 34, 107, 208 NICE NICE SACT √
TRASTUZUMAB EMTANSINE CANCER NHS ENGLAND CANCER EXCLUSION TA 458 NICE NICE SACT √ √
TRIFLURIDINE–TIPIRACIL CANCER NHS ENGLAND CANCER EXCLUSION TA 405 NICE NICE SACT √ √
TREATMENT OF TOXIXITY WITH 5-FU NHS ENGLAND URGENT POLICY
URIDINE TRIACETATE NHS ENGLAND CANCER EXCLUSION NHS ENGLAND POLICY NHS ENGLAND POLICY √ √
AND CAPECITABINE STATEMENT 1929
TA 487 NICE NICE
VENETOCLAX CANCER NHS ENGLAND/CDF CANCER EXCLUSION SACT √ √
CDF CDF CDF
* DRUG IS BEING REPATRIATED FROM PRIMARY TO SECONDARY CARE THEREFORE SUPPLY ROUTE MAY VARY AT PRESENT
** ROUTINELY COMMISSIONED IN COMBINATION WHEN DUAL THERAPY REQUIRED
*** ONLY WHEN PRESCRIBED IN AN ADULT SPECIALIST CENTRE

**** ONLY WHERE IT IS A RECOGNISED MS CENTRE WITH SPECIALIST NURSE SUPPORT
NEW LINES ADDED TO V15 LIST

CHANGES TO V14 19/20 LIST
ADDITIONAL NOTES:
1. WHERE THE FUNDED INDICATION IS FOR PAEDIATRIC USE THE CCG WILL BECOME THE RESPONSIBLE COMMISSIONER WHEN THE PATIENT IS TRANSFERRED TO THE ADULT SERVICE
2. CCGS ARE THE RESPONSIBLE COMMISSIONER FOR RITUXIMAB IN ADULT NON CANCEROUS HAEMOTOLOGICAL CONDITIONS (EG ITP) AND NON SPECIALIST AUTO-INFLAMMATORY CONDITIONS (EG RA)
3. ELTROMBOPAG AND ROMIPLOSTIM ARE THE RESPONSIBILTY OF CCGS REGARDLESS OF THE CAUSE OF THE THROMBOCYTOPENIA IN ADULTS (PAEDIATRICS ARE NHS
ENGLAND RESPONSIBILITY)
4. IT IS A MANDATED REQUIREMENT THAT ALL USE OF CHEMOTHERAPY IS RECORDED IN THE SACT DATABASE INCLUDING THOSE TREATMENTS FUNDED THROUGH THE CDF
5. USE IN VASCULAR DISEASE IS COMMISSIONED BY NHS ENGLAND WITHIN SPECIALIST CENTRES - CCG's ARE RESPONSIBLE FOR ALL OTHER INDICATIONS
6. NHS ENGLAND IS THE RESPONSIBLE COMMISSIONER WHEN SOMATROPIN ANALOGUES (GROWTH HORMONE) ARE PRESCRIBED IN SPECIALIST CENTRES FOR INDICATIONS FALLING OUTSIDE NICE GUIDANCE
7. NHS ENGLAND COMMISSIONS ARVS AS PER PUBLISHED POLICIES, FOR THE TREATMENT OF PEOPLE WITH DIAGNOSED HIV INFECTION AND FOR THOSE THOUGHT TO BE HIV POSITIVE (POST EXPOSURE PROPHYLAXIS). NHS ENGLAND DOES NOT ROUTINELY COMMISSION PRE-EXPOSURE PROPHYLAXIS AND THIS IS ONLY AVAILABLE TO THOSE
ENROLLED IN CLINICAL STUDIES OR OTHER NHS ENGLAND AGREED SCHEMES
8.DRUGS APPROVED BY NICE FOR ADULT CONDITIONS WILL BE COMMISSIONED IN CHILDREN AT SPECIALISED PAEDIATRIC CENTRES IF THE PATIENT MEETS THE NICE CRITERIA AND THERE IS EVIDENCE TO SUGGEST THAT THE DRUG IS SAFE AND CLINICALLY APPROPRIATE TO USE IN CHILDREN AS PER THE NHS ENGLAND MEDICINES FOR
CHILDREN POLICY FOUND AT https://www.england.nhs.uk/publication/commissioning-medicines-for-children-specialised-services/ AND A BLUETEQ FORM IS AVAILABLE. THIS INCLUDES FOR DRUGS NORMALLY COMMISISONED BY CCG'S IN ADULTS EG ADALIMUMAB, ETANERCEPT, INFLIXIMAB ETC PLEASE NOTE THAT MEDICINES FUNDED UNDER THE NHS
ENGLAND MEDICINES FOR CHILDREN POLICY MAY HAVE ADDITIONAL CRITERIA WITH RESPECT TO ACCESS
9. PLEASE NOTE THIS IS A NOT LIVE LIST AND THE COMMISSIONING POSITION MAY CHANGE PRIOR TO A NEW LIST BEING PUBLISHED IN MARCH OF EACH YEAR - REFER TO THE NICE POLICY PROGRAMME ON THE NICE WEBSITE AND/OR THE NHS ENGLAND POLICY PROGRAMME PUBLSIHED AT
https://www.england.nhs.uk/publication/clinical-commissioning-policy-work-programme/
10. Products that are currently available via the Early Access to Medicines Scheme are not covered by this list but all require registration via the Blueteq system

NHS England Drugs List v15 2020 2021 PDF

Uploaded by

Document Information

Original Title

Copyright

Available Formats

Share this document

Share or Embed Document

Sharing Options

Did you find this document useful?

Is this content inappropriate?

Copyright:

Available Formats

NHS England Drugs List v15 2020 2021 PDF

Uploaded by

Copyright:

Available Formats

MEDICINES NOT REIMBURSED THROUGH NATIONAL PRICES AND DIRECTLY COMMISSIONED BY NHS ENGLAND

VERSION 15 PUBLISHED APRIL 2020

NHS ENGLAND CLINICAL

NHS ENGLAND CLINICAL

TA259, 387 (SEE ALSO SSC1438)

NHS ENGLAND CLINICAL

HIGHLY SPECIALISED HIGHLY SPECIALISED

NOT ROUTINELY COMMISSIONED

DRUGS USED IN METABOLIC HIGHLY SPECIALISED HIGHLY SPECIALISED

NUMBER OF PATIENTS TREATED

APLASTIC ANAEMIA DRUGS USED IN HYPOPLASTIC,

ANTITHYMOCYTE APLASTIC ANAEMIA DRUGS USED IN HYPOPLASTIC,

HIV IN COMBINATION WITH OTHER ANTI-

TA129, TA228, TA311, TA378, TA573

TORSION DYSTONIAS AND OTHER

THROMBOTIC THROMBOCYTOPENIC NOT ROUTINELY COMMISSIONED

NUMBER OF PATIENTS TREATED

NOT ROUTINELY COMMISSIONED

CEREBROTENDINOUS DRUGS USED IN METABOLIC NHS ENGLAND CLINICAL

NHS ENGLAND CLINICAL

NHS ENGLAND CLINICAL

NOT ROUTINELY COMMISSIONED

NHS ENGLAND CLINICAL

NHS ENGLAND CLINICAL

PRIMARY HYPO AND HYPERKALAEMIC

HIV IN COMBINATION WITH OTHER ANTI-

DRUGS AFFECTING THE IMMUNE

NHS ENGLAND CLINICAL

NHS NATIONAL SPECIALISED

DRUGS AFFECTING THE IMMUNE

VIRAL HEPATITIS (B&C) &

NHS ENGLAND CLINICAL

HYPERPARATHYROIDISM - DIALYSIS DRUGS FOR MINERAL BONE

HIV IN COMBINATION WITH OTHER ANTI-

TREATMENT OF ADULT PATIENTS WITH

AS PER BCSH GUIDELINES FOR

AS PER BCSH GUIDELINES FOR

VIRAL HEPATITIS (B&C) &

HIV iN COMBINATION WITH OTHER ANTI-

DRUGS USED IN METABOLIC HIGHLY SPECIALISED HIGHLY SPECIALISED

CHRONIC GRAFT VERSUS HOST NHS ENGLAND CLINICAL

CLINICAL GUIDELINES FOR

NUMBER OF PATIENTS TREATED

PRODUCT WITH LOWEST

HIGHLY SPECIALISED HIGHLY SPECIALISED

PRODUCT WITH LOWEST

HIGHLY SPECIALISED HIGHLY SPECIALISED

GROWTH HORMONE & GROWTH

GROWTH HORMONE & GROWTH NHS ENGLAND CLINICAL

NHS ENGLAND CLINICAL

DRUGS USED IN METABOLIC

GROWTH HORMONE & GROWTH

PRODUCT WITH LOWEST

HIGHLY SPECIALISED HIGHLY SPECIALISED

PRODUCT WITH LOWEST

ONLY WHEN DURATION OF PN IS > 14

ROUTINELY COMMISSIONED AS PER

LYSOSOMAL STORAGE DISORDER

HYPOTHALMIC & ANTERIOR PITUITARY NHS ENGLAND CLINICAL

TA 357, TA366, TA428, TA531

FOCAL SEGMENTAL NOT ROUTINELY COMMISSIONED

TA65, TA137, TA174, TA193, TA65, TA137, TA174, TA193,

AS PER CIRCULAR IE ONLY